



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/00, 9/10, 9/24, 9/38	A1	(11) International Publication Number: WO 00/29558 (43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/US99/26807 (22) International Filing Date: 11 November 1999 (11.11.99) (30) Priority Data: PA 1998 01483 13 November 1998 (13.11.98) DK (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US PA 1998 01483 (CIP) Filed on 13 November 1998 (13.11.98) (71)(72) Applicant and Inventor: CLAUSEN, Henrick [DK/DK]; Norske Alle 3, DK-2840 Holte (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): AMADO, Margarida [PT/US]; 3137-L Via Alicante, La Jolla, CA 92037 (US). (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: UDP-GALACTOSE: β -N-ACETYL-GLUCOSAMINE β 1,3GALACTOSYLTRANSFERASES, β 3GAL-T5 (57) Abstract <p>A novel gene defining a novel enzyme in the UDP-D-galactose: β-N-acetylglucosamine/β-N-acetylgalactosamine β1,3galactosyltransferase family, termed β3Gal-T5, with unique enzymatic properties is disclosed. The enzymatic activity of β3Gal-T5 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding β3Gal-T5 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting β3Gal-T5 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing β3Gal-T5. The enzyme β3Gal-T5 and β3Gal-T5-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of β3Gal-T5. Further, the invention discloses methods of obtaining β1,3galactosyl glycosylated saccharides, glycopeptides or glycoproteins by use of an enzymically active β3Gal-T5 protein or fusion protein thereof or by using cells stably transfected with a vector including DNA encoding an enzymatically active β3Gal-T5 protein as an expression system for recombinant production of such glycopeptides or glycoproteins. Also a method for the identification of DNA sequence variations in the β3Gal-T5 gene by isolating DNA from a patient, amplifying β3Gal-T5-coding exons by PCR, and detecting the presence of DNA sequence variation, are disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**UDP-GALACTOSE: β -N-ACETYL-
GLUCOSAMINE β 1,3 GALACTOSYLTRANSFERASES, β 3GAL-T5**

This invention claims priority in the United States under 35 U.S.C. § 119 to Denmark Application No. PA 1998 01483 filed November 13, 1998, which application is
5 incorporated by reference herein in its entirety.

1. FIELD OF THE INVENTION

The present invention relates generally to the biosynthesis of glycans found
10 as free oligosaccharides or covalently bound to proteins and glycosphingolipids. This invention is more particularly related to a family of nucleic acids encoding UDP-D-galactose: β N-acetylglucosamine β 1,3-galactosyltransferases (β 3Gal-transferases), which add galactose to the hydroxy group at carbon 3 of 2-acetamido-2-deoxy-D-glucose (GlcNAc). This invention is more particularly related to a gene encoding the fifth member
15 of the family of β 3Gal-transferases, termed β 3Gal-T5, probes to the DNA encoding β 3Gal-T5, DNA constructs comprising DNA encoding β 3Gal-T5, recombinant plasmids and recombinant methods for producing β 3Gal-T5, recombinant methods for stably transfecting cells for expression of β 3Gal-T5, and methods for indication of DNA polymorphism in patients.

20

2. BACKGROUND OF THE INVENTION

A family of UDP-galactose; β -N-acetyl-glucosamine β 1-3galactosyl-transferases (β 3Gal-T's) was recently identified (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a
25 UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Kolbinger, F., Streiff, M.B. and Katopodis, A.G. Cloning of a human UDP-galactose:2- acetamido-2-deoxy-D-glucose β 3-galactosyltransferase catalysing the formation of type 1 chains. *J. Biol. Chem.* 273:433-440, 1998; Hennett, T., Dinter, A., Kuhnert, P., Mattu, T.S., Rudd, P.M. and Berger, E.G.
30 Genomic cloning and expression of three murine UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase genes. *J. Biol. Chem.* 273:58-65, 1998; Miyaki, H., Fukumoto, S., Okada, M., Hasegawa, T. and Furukawa, K. Expression cloning of rat cDNA encoding UDP-galactose G(D2) β 1,3 galactosyltransferase that determines the expression of G(D1

b)/G(M 1)G(A1). *J. Biol. Chem.* 272:24794-24799, 1997). Three genes within this family, β 3Gal-T1, -T2, and -T3, encode β 3galactosyltransferases that form the Gal β 1-3GlcNAc linkage. The type 1 chain Gal β 1-3GlcNAc sequence is found in both N- and O-linked oligosaccharides of glycoproteins and in lactoseries glycosphingolipids, where it is the counterpart of type 2 Gal β 1-4GlcNAc poly-N-acetyllactosamine structures (Kobata. A. Structures and functions of the sugar chains of glycoproteins. *Eur J Biochem* 209:483-501, 1992.). Type 1 chain structures are found mainly in endodermally derived epithelia, whereas the type 2 chains are found in ecto- and mesodermally derived cells including erythrocytes (Oriol, R., Le Pendu, J. and Mollicone, R. Genetics of ABO, H, Lewis, X and related antigens. *Vox Sanguinis* 51:161-171, 1986; Clausen, H. and Hakomori, S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. *Vox Sanguinis* 56:1-20, 1989). Normal gastro-intestinal epithelia express mainly type 1 chain glycoconjugates, while type 2 chain structures are predominantly expressed in tumors (Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. *Advances in Cancer Research* 52:257-331, 1989; Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. *Cancer Res* 56:5309-5318, 1996). It is of considerable interest to define the gene(s) responsible for formation of these core structures in normal and malignant epithelia. Several characteristics of the three previously described β 3Gal-Ts capable of forming type 1 chain structures suggest that these are not the major enzyme(s) involved in type 1 chains synthesis in epithelia: (i) Northern analysis indicates that β 3Gal-T1 and -T2 are exclusively expressed in brain (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Kolbinger, F., Streiff, M.B. and Ktopodis, A.G. Cloning of a human UDP-galactose:2- acetamido-2-deoxy-D-glucose β 3-galactosyltransferase catalysing the formation of type 1 chains. *J. Biol. Chem.* 273:433-440, 1998; Hennett, T., Dinter, A., Kuhnert, P., Mattu, T.S., Rudd, P.M. and Berger, E.G. Genomic cloning and expression of three murine UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase genes. *J. Biol. Chem.* 273:58-65, 1998); (ii) although β 3Gal-T3

has a wider expression pattern it is not detected in several tissues including colon and it is weakly expressed in gastric mucosa (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Kolbinger, F., Streiff, M.B. and Ktopodis, A.G. Cloning of a human UDP-galactose:2- acetamido-2-deoxy-D-glucose β 3-galactosyltransferase catalysing the formation of type 1 chains. *J. Biol. Chem.* 273:433-440, 1998); (iii) the kinetic properties of recombinant enzymes are not consistent with those reported for β 3Gal-T activities in epithelia (Sheares, B.T., Lau, J.T. and Carlson, D.M. Biosynthesis of galactosyl-beta 1,3-N- acetylglucosamine. *J. Biol. Chem.* 257:599-602, 1982; Holmes, E.H. Characterization and membrane organization of beta 1----3- and beta 1---4- galactosyltransferases from human colonic adenocarcinoma cell lines Cob 205 and SW403: basis for preferential synthesis of type 1 chain lacto-series carbohydrate structures. *Arch Biochem Biophys* 270:630-646, 1989); and (iv) the acceptor substrate specificities of β 3Gal-T1, -T2, or -T3 do not include the mucin-type core 3 structure (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Hennett, T., Dinter, A., Kuhnert, P., Mattu, T.S., Rudd, P.M. and Berger, E.G. Genomic cloning and expression of three murine UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase genes. *J. Biol. Chem.* 273:58-65, 1998), which was previously found to be a highly efficient substrate for β 3Gal-T activity isolated from porcine trachea (Sheares, B.T. and Carlson, D.M. Characterization of UDP-galactose:2-acetamido-2-deoxy-D- glucose 3 beta-galactosyltransferase from pig trachea. *J. Biol. Chem.* 258:9893-9898, 1983).

Access to additional existing β GlcNAc β 3Gal-transferase genes encoding β 3Gal-transferases with better kinetic properties than β 3Gal-T1, -T2, and -T3 would allow production of more efficient enzymes for use in galactosylation of oligosaccharides, glycoproteins, and glycosphingolipids. Such enzymes could be used, for example, in pharmaceutical or other commercial applications that require synthetic galactosylation of these or other substrates that are not or poorly acted upon by β 3Gal-T1, -T2, and -T3, in

order to produce appropriately glycosylated glycoconjugates having particular enzymatic, immunogenic, or other biological and/or physical properties.

Consequently, there exists a need in the art for additional isolated UDP-
5 galactose: β -N-acetyl-glucosamine β 1-3Galactosyltransferases having unique, specific properties and the primary structure of the genes encoding these enzymes. The present invention meets this need, and further presents other related advantages, as described in detail below.

10 3. SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids encoding human UDP-
galactose: β 3-N-acetylglucosamine β 1,3-galactosyltransferase (β 3Gal-T5), including cDNA
and genomic DNA. β 3Gal-T5 has better kinetic properties than β 3Gal-T1, -T2, and T3, as
exemplified by its better activity with saccharide derivatives and glycoprotein substrates as
15 well as its activity with globoside glycolipid. Indeed, β 3Gal-T5 is the first
glycosyltransferase available for transfer of Gal β 1-3 to globoside (GalNAc β 1-3Gal α 1-
4Gal β 1-4Glc β 1-Cer). The complete nucleotide sequence of β 3Gal-T5, is set forth in Figure
1.

In one aspect, the invention encompasses isolated nucleic acids comprising
20 or consisting of the nucleotide sequence of nucleotides 1-933 as set forth in Figure 1, or
sequence-conservative or function-conservative variants thereof. Also provided are isolated
nucleic acids hybridizable with nucleic acids having the sequence as set forth in Figure 1 or
fragments thereof or sequence-conservative or function-conservative variants thereof. In
various embodiments, the nucleic acids of the invention are hybridizable with β 3Gal-T5
25 sequences under conditions of low stringency, intermediate stringency, high stringency, or
specific preferred stringency conditions defined herein. In one embodiment, the DNA
sequence encodes the amino acid sequence, as set forth in Figure 1, from methionine (amino
acid no. 1) to valine (amino acid no. 310). In another embodiment, the DNA sequence
encodes an amino acid sequence comprising a sequence from methionine (no. 25) to valine
30 (no. 310) as set forth in Figure 1.

In a related aspect, the invention provides nucleic acid vectors comprising
 β 3Gal-T5 DNA sequences, including but not limited to those vectors in which the β 3Gal-

T5 DNA sequence is operably linked to a transcriptional regulatory element (e.g. a promoter, an enhancer, or both), with or without a polyadenylation sequence. Cells comprising these vectors are also provided, including without limitation transiently and stably expressing cells. Viruses, including bacteriophages, comprising β 3Gal-T5-derived DNA sequences are also provided. The invention also encompasses methods for producing β 3Gal-T5 polypeptides. Cell-based methods include without limitation those comprising: introducing into a host cell an isolated DNA molecule encoding β 3Gal-T5, or a DNA construct comprising a DNA sequence encoding β 3Gal-T5; growing the host cell under conditions suitable for β 3Gal-T5 expression; and isolating β 3Gal-T5 produced by the host cell. Further, this invention provides a method for generating a host cell with *de novo* stable expression of β 3Gal-T5 comprising: introducing into a host cell an isolated DNA molecule encoding β 3Gal-T5 or an enzymatically-active fragment thereof (such as, for example, a polypeptide comprising amino acids 25-310 as set forth in Figure 1), or a DNA construct comprising a DNA sequence encoding β 3Gal-T5 or an enzymatically active fragment thereof; selecting and growing host cells in an appropriate medium; and identifying stably transfected cells expressing β 3Gal-T5. The stably transfected cells may be used for the production of β 3Gal-T5 enzyme for use as a catalyst and for recombinant production of peptides or proteins with appropriate galactosylation. For example, eukaryotic cells, whether normal or diseased cells, having their glycosylation pattern modified by stable transfection as above, or components of such cells, may be used to deliver specific glycoforms of glycopeptides and glycoproteins, such as, for example, as immunogens for vaccination.

In yet another aspect, the invention provides isolated β 3Gal-T5 polypeptides, including without limitation polypeptides having the sequence set forth in Figure 1, polypeptides having the sequence of amino acids 25-310 as set forth in Figure 1, and a fusion polypeptide consisting of at least amino acids 25-310 as set forth in Figure 1 fused in frame to a second sequence, which may be any sequence that is compatible with retention of β 3Gal-T5 enzymatic activity in the fusion polypeptide. Suitable second sequences include without limitation those comprising an affinity ligand, a reactive group, and/or a functional domain from another protein.

In another aspect of the present invention, methods are disclosed for screening for mutations in the coding region (exon I) of the β 3Gal-T5 gene using genomic DNA isolated from, e.g., blood cells of normal and/or diseased subjects. In one
 5 embodiment, the method comprises: isolation of DNA from a normal or diseased subject; PCR amplification of coding exon I; DNA sequencing of amplified exon DNA fragments and establishing therefrom potential structural defects of the β 3Gal-T5 gene associated with disease.

These and other aspects of the present invention will become evident upon
 10 reference to the following detailed description and drawings.

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the DNA sequence of the β 3Gal-T5 gene (SEQ ID NO:8) and
 15 the predicted amino acid sequence of β 3Gal-T5 (SEQ ID NO:9). The amino acid sequence is shown in single-letter amino acid code. The hydrophobic segment representing the putative transmembrane domain is *underlined* with a *double line* (Kyte & Doolittle, window of 8 (Kyte, J. and Doolittle, R.F. A simple method for displaying the hydropathic character of a protein. *Journal of Molecular Biology* 157:105-132, 1982)). Three consensus motifs
 20 for *N*-glycosylation are indicated by *asterisks*. The location of the primers used for preparation of the expression constructs are indicated by *single underlining*. The single-letter amino acid code corresponds to the three-letter amino acid code of the Sequence Listing set forth hereinbelow, as follows: A, Ala; R, Arg; N, Asn; D, Asp; B, Asx; C, Cys; Q, Gln; E, Glu; Z, Glx; G, Gly; H, His; I, Ile; L, Leu; K, Lys; M, Met; F, Phe; P, Pro; S,
 25 Ser; T, Thr; W, Trp; Y, Tyr; and V, Val.

FIG. 2 is an illustration of multiple sequence analysis (ClustalW) of five human β 3Gal-transferases. The transferases are listed according to order of similarity with β 3Gal-T1. The SEQ ID NOs for the transferases shown are as follows: β 3Gal-T1 (SEQ ID
 30 NO:11), β 3Gal-T2 (SEQ ID NO:10), β 3Gal-T3 (SEQ ID NO:12), β 3Gal-T4 (SEQ ID NO:13) and β 3Gal-T5 (SEQ ID NO:9). Introduced gaps are shown as *hyphens*, and aligned identical residues are *boxed* (*black* for all sequences, *dark grey* for four sequences, and *light*

grey for three sequences). The putative transmembrane domains are *underlined* with a
single line. The positions of conserved cysteines are indicated by *asterisks*. One conserved
N-glycosylation site is indicated by an *open circle*. The DxD motif is indicated by an
 5 *arrow*.

FIG. 3 is a schematic depiction of β 3Gal-transferases aligned for the
 conserved cysteine residues. Potential *N*-glycosylation sites are indicated by *trees*.
 Cysteine residues are indicated by the *letter C*, and conservation of cysteines are indicated
 10 by *stippled lines* between genes. The position of conserved sequence motifs as shown in
 Figure 2 are indicated with *dotted lines* and amino acid sequences. The putative
 transmembrane signal is indicated by *thick lines*.

FIG. 4 depicts sections of a 1-D ^1H -NMR spectrum of the β 3Gal-T5 product
 15 with Core3-*p*NPh, Gal β 1-3GlcNAc β 1-3GalNAc α 1-1*p*NPh, showing all non-exchangeable
 monosaccharide ring methine and exocyclic methylene resonances. Residue designations
 for the Gal β 1-3(Gal β 3), GlcNAc β 1-3 (GlcNAc β 3), GalNAc α 1-1(α) are followed by
 proton designations (Braunschweiler, L. and Ernst, R.R. Coherence transfer by isotropic
 mixing: Application to proton correlation spectroscopy. *J. Magn. Reson.* 53:521-528, 1983;
 20 Bax, A. and Davis, D.G. MLEV-1 7-based two-dimensional homonuclear magnetization
 transfer spectroscopy. *J. Magn. Reson.* 65:355-360, 1985a; Bothner-By, A.A., Stephens,
 R.L., Lee, J.M., Warren, C.D. and Jeanloz, R.W. Structure determination of a
 tetrasaccharide: Transient nuclear Overhauser effects in the rotating frame. *J. Am. Chem.*
Soc 106:811-813, 1984; Bax, A. and Davis, D.G. Practical aspects of two-dimensional
 25 transverse NOE spectroscopy. *J. Magn. Reson.* 63:207-213, 1985b; Keeler, J., Laue, E.D.
 and Moskau, D. Experiments for recording pure-absorption heteronuclear correlation
 spectra using pulsed field gradients. *J. Magn. Reson.* 98:207-216, 1992; Bodenhausen, G.
 and Ruben, D.J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear
 spectroscopy. *Chem. Phys. Lett.* 69:185-189, 1980).

FIG. 5 is a photographic illustration of Northern blot analysis of human
 tumor cell lines. Human pancreatic adenocarcinoma cell lines AsPC-1, BxPC-3, Capan-1,
 30

Capan-2, Colo357, HPAF, PANC-1, Suit2, S2-013, and the HT29 colon adenocarcinoma cell line were probed with ³²P-labeled cDNA of β3Gal-T5 corresponding to the soluble expression construct.

5

5. DETAILED DESCRIPTION OF THE INVENTION

All patent applications, patents, and literature references cited in this specification are hereby incorporated by reference in their entirety. In the case of conflict, the present description, including definitions, is intended to control.

10

5.1. DEFINITIONS

1. "Nucleic acid" or "polynucleotide" as used herein refers to purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as "protein nucleic acids" (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases (see below).

2. "Complementary DNA or cDNA" as used herein refers to a DNA molecule or sequence that has been enzymatically synthesized from the sequences present in an mRNA template, or a clone of such a DNA molecule. A "DNA Construct" is a DNA molecule or a clone of such a molecule, either single- or double-stranded, which has been modified to contain segments of DNA that are combined and juxtaposed in a manner that would not otherwise exist in nature. By way of non-limiting example, a cDNA or DNA which has no introns is inserted adjacent to, or within, exogenous DNA sequences.

3. A plasmid or, more generally, a vector, is a DNA construct containing genetic information that may provide for its replication when inserted into a host cell. A plasmid generally contains at least one gene sequence to be expressed in the host cell, as well as sequences that facilitate such gene expression, including promoters and transcription initiation sites. It may be a linear or closed circular molecule.

4. Nucleic acids are "hybridizable" to each other when at least one strand of one nucleic acid can anneal to another nucleic acid under defined stringency conditions. Stringency of hybridization is determined, e.g., by a) the temperature at which

hybridization and/or washing is performed, and b) the ionic strength and polarity (e.g., formamide) of the hybridization and washing solutions, as well as other parameters.

Hybridization requires that the two nucleic acids contain substantially complementary sequences; depending on the stringency of hybridization, however, mismatches may be tolerated. Typically, hybridization of two sequences at high stringency (such as, for example, in an aqueous solution of 0.5X SSC, at 65°C) requires that the sequences exhibit some high degree of complementarity over their entire sequence. Conditions of intermediate stringency (such as, for example, an aqueous solution of 2X SSC at 65°C) and low stringency (such as, for example, an aqueous solution of 2X SSC at 55°C), require correspondingly less overall complementarity between the hybridizing sequences. (1X SSC is 0.15 M NaCl, 0.015 M Na citrate.)

In one embodiment, this invention provides nucleic acids which are hybridizable to a β 3Gal-T5 nucleic acid under the following hybridization conditions: a full-length or soluble β 3Gal-T5 expression construct (*see Examples*) is used as probe (*e.g.* by random primed labeling) against a DNA or RNA blot, the blot is probed overnight at 42°C as previously described (Bennett et al., 1996, cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine, Polypeptide N-acetyl-galactosaminyl-transferase, GalNAc-T3, *J. Biol. Chem.* 271, 17006-17012), washed 2 x 10 min at room temperature (RT; from 18 to 23°C) with 2 x SSC, 1% Na₄P₂O₇, 2 x 20 min at 65°C with 0.2 x SSC, 1 % SDS, 1% Na₄P₂O₇ and once 10 min with 0.2 x SSC at RT ("preferred hybridization conditions"). Under these preferred hybridization conditions, there is no cross-hybridization between β 3Gal-T5 and the previously-identified β 3Gal-Ts (*i.e.* β 3Gal-T1, -T2, -T3, and T4; *see also* Amado et al., 1998, A family of human β 3-galactosyltransferases: characterization of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family, *J. Biol. Chem.* 273, 12770-12778).

5. An "isolated" nucleic acid or polypeptide as used herein refers to a component that is removed from its original environment (for example, its natural environment if it is naturally occurring). An isolated nucleic acid or polypeptide contains less than about 50%, preferably less than about 75%, and most preferably less than about 90%, of the cellular components with which it was originally associated.

6. A "probe" refers to a nucleic acid that forms a hybrid structure with a sequence in a target region due to complementarity of at least one sequence in the probe with a sequence in the target region.

5 7. A nucleic acid that is "derived from" a designated sequence refers to a nucleic acid sequence that corresponds to a region of the designated sequence. This encompasses sequences that are homologous or complementary to the sequence, as well as "sequence-conservative variants" and "function-conservative variants". Sequence-conservative variants are those in which a change of one or more nucleotides in a given
10 codon position results in no alteration in the amino acid encoded at that position. Function-conservative variants of β 3Gal-T5 are those in which a given amino acid residue in the polypeptide has been changed without altering the overall conformation and enzymatic activity (including substrate specificity) of the native polypeptide; these changes include, but are not limited to, replacement of an amino acid with one having similar physico-
15 chemical properties (such as, for example, acidic, basic, hydrophobic, and the like).

8. A "donor substrate" is a molecule recognized by, e.g., a galactosyltransferase and that contributes a galactosyl moiety for the transferase reaction. For β 3Gal-T5, a donor substrate is UDP-galactose. An "acceptor substrate" is a molecule, preferably a saccharide or oligosaccharide, that is recognized by, e.g., a galactosyltransferase
20 and that is the target for the modification catalyzed by the transferase, i.e., receives the galactosyl moiety. For β 3Gal-T5, acceptor substrates include without limitation oligosaccharides, glycoproteins, O-linked GlcNAc-glycopeptides, O-linked GalNAc-glycopeptides, and glycosphingolipids containing the sequences, GlcNAc β 1-6Gal, GlcNAc β 1-6GalNAc, GlcNAc β 1-3 GalNAc, GlcNAc β 1-2Man, GlcNAc β 1-4Man,
25 GlcNAc β 1-6Man, GlcNAc β 1-3Man, Glc β 1-ceramide, and GalNAc β 1-3Gal.

The present invention provides the isolated DNA molecules, including genomic DNA and cDNA, encoding the UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase (β 3Gal-T5).

β 3Gal-T5 was identified by analysis of EST database sequence information,
30 and cloned based on EST and 5'RACE cDNA clones. The cloning strategy may be briefly summarized as follows: 1) synthesis of oligonucleotides derived from EST sequence information, designated EBER1301 and EBER 1302; 2) PCR screening and isolation of a

P1 genomic DNA phage containing the entire coding region of β 3Gal-T5; 3) sequencing of P1 DNA; 4) identification of a novel DNA sequence corresponding to β 3Gal-T5; 5) construction of expression constructs by reverse-transcription-polymerase chain reaction (RT-PCR) using human P1 DNA; 6) expression of the cDNA encoding β 3Gal-T5 in Sf9 (*Spodoptera frugiperda*) cells. More specifically, the isolation of a representative DNA molecule encoding a novel fifth member of the mammalian UDP-galactose: β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-galactosyltransferase family involved the following procedures described below.

5.2. IDENTIFICATION AND CLONING OF HUMAN β 3Gal-T5

A novel gene, with significant sequence similarity to the β 3Gal-transferase gene family was identified (Fig 1), using the strategy as previously described (Almeida, R., Amado, M., David, L., et al. A Family of Human β 4-Galactosyltransferases: Cloning and expression of two novel UDP-Galactose β -N-Acetylglucosamine β 1,4-Galactosyltransferases, β 4Gal-T2 and β 4Gal-T3. *J.Biol.Chem.* 272:31979-31992, 1997). The predicted coding region of β 3Gal-T5 included two potential initiation codons, preceding a hydrophobic sequence, of which the second is in agreement with Kozak's rule (Kozak, M. Regulation of translation in eukaryotic systems. *Ann Rev Cell Biol* 8:197-225, 1992) (Fig. 1). The predicted coding sequence indicates that β 3Gal-T5 is an type II transmembrane glycoprotein with a N-terminal cytoplasmic domain of 2 or 7 residues, a transmembrane segment of 19 residues flanked by charged residues, and a stem region and catalytic domain of 284 residues with three potential N-glycosylation sites (Fig. 1). A Kyte and Doolittle hydropathy plot (Kyte, J. and Doolittle, R.F. A simple method for displaying the hydropathic character of a protein. *Journal of Molecular Biology* 157:105-132, 1982) indicated that the putative stem region was hydrophilic similar to β Gal-T1, -T2 and -T3 (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterization of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998). In contrast, β 3Gal-T4, with exclusive glycolipid specificity has a hydrophobic stem region (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-

acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Miyaki, H., Fukumoto, S., Okada, M., Hasegawa, T. and Furukawa, K. Expression cloning of rat cDNA encoding UDP-galactose G(D2) β 1,3 galactosyltransferase that determines the expression of G(D1 b)/G(M 1)G(A1). *J. Biol. Chem.* 272:24794-24799, 1997).

A multiple sequence alignment of five β 3Gal-transferases is shown in Figure 2. The β 3Gal-T5 gene has highest similarity to β 3Gal-T2. Similarities among the five human genes are found predominantly in the central regions; there were no significant similarities in the NH₂-terminal regions. Several motifs in the putative catalytic domains are conserved between all the sequences. Noteworthy, three cysteine residues are aligned within all the human genes, and three additional are aligned within β 3Gal-T1, -T2, -T3 and -T5 (Fig. 2, Fig. 3). One potential N-linked glycosylation site, occurs in the central region of the putative catalytic domains, and is conserved in all sequences. Similarly, a single N-linked glycosylation site was conserved among all members of β 4Gal-T gene family (Schwientek, T., Almeida, R., Levery, S.B., Holmes, E., Bennett, E.P. and Clausen, H. Cloning of a novel member of the UDP-galactose: β -N-acetylglucosamine β 1,4-galactosyltransferase family, β 4Gal-T4, involved in glycosphingolipid biosynthesis. *J. Biol. Chem.* 273:29295-29305, 1998 Schwientek et al., 1998). The DXD motif, recently shown to be conserved among several glycosyltransferases gene families (Wiggins, C.A.R. and Munro, S. Activity of the yeast MNN1 α -1,3-mannosyltransferase requires a motif conserved in many other families of glycosyltransferases. *Proc. Natl. Acad. Sci. USA* 95:7945-7950, 1998; Breton, C., Bettler, E., Joziassse, D.H., Geremia, R.A. and Imberty, A. Sequence-function relationships of prokaryotic and eukaryotic galactosyltransferases. *J. Biochem* 123:1000-1009, 1998), is also present in all human β 3Gal-transferases.

5.3. GENOMIC ORGANIZATION AND CHROMOSOMAL

LOCALIZATION OF β 3GAL-T5, BGALT5

The coding region of β 3Gal-T5 was determined by sequencing of P1 clones to be located in a single exon, similar to β Gal-T1, -T2, -T3 and -T4 (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-

Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998). This was confirmed in a recently released 164 kb genomic sequence (GenBank accession number AF064860). *BGALT5* is located on chromosome 21q22.3. The other three genes in the family are located on different chromosomes *BGALT2* (1q31), *-T3* (3q25), and *-T4* (6p21 .3) (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998).

10

5.4. EXPRESSION OF β 3GAL-T5 IN INSECT CELLS

Expression of a soluble construct of β 3Gal-T5 in Sf9 cells resulted in a marked increase (20-30 fold) in galactosyltransferase activity using acceptor substrates containing terminal β GlcNAc, when compared to uninfected cells or cells infected with irrelevant constructs (not shown). Analysis of the substrate specificity of partially purified β 3Gal-T5 activity showed that all effective substrates contained β GlcNAc at the nonreducing end (Table I).

20

25

30

Table I Substrate specificity of β Gal-T5 with saccharide acceptors

	Substrate concentration	β Gal-T5 ^a	
		1 mM	5 mM
5		nmol/min/ml	
	D-GlcNAc	0.5	1.2
	β -D-GlcNAc-Bzl ^b	1.5	3.9
	β -D-GlcNAc-1- <i>p</i> -Nph	2.1	6.9
10	β -D-GlcNAc-1-thio- <i>p</i> -Nph	1.1	3.4
	β -D-GlcNAc-Me-umb	2.6	7.5
	β -D-GalNAc-Me-umb	0.0	0.0
	α -D-GlcNAc-Bzl	0.0	0.0
	α -D-GalNAc-Bzl	0.0	0.0
15	α -D-Gal-1- <i>o</i> -Nph	0.0	0.0
	β -D-Gal-1- <i>o</i> -Nph	0.0	0.0
	β -D-Glc-Me-umb	0.0	0.0
	β -Gal-(1-4)- β -D-Xyl-1-Me-umb ^c	0.0	0.0
	β -D-GlcNAc-(1-3)- β -D-Gal-1-Me	27.4	87.4
20	β -D-GlcNAc-(1-3)- α -D-GalNAc- <i>p</i> -Nph	10.8	34.4
	β -D-GlcNAc-(1-6)- α -D-Man-1-Me	4.0	13.0
	β -D-GlcNAc-(1-2)- α -D-Man	0.0	3.0
	β -D-GlcNAc-(1-2)- α -D-Man-(1-3)-[β -D-GlcNAc-(1-2)- α -D-Man-(1-6)]D-Man	0.0	0.0

25

^a Enzyme partially purified as described elsewhere herein.^b Bzl, benzyl; Me, methyl; Me-Umb, 4-methyl-umbelliferyl; Nph, nitrophenyl.^c prepared enzymatically using β -D-Xyl-1-Me-Umb and UDP-Gal as substrates (R. Almeida, H. Clausen, unpublished).

30 Among the simple saccharide derivatives tested disaccharide β -D-GlcNAc-(1-3)- β -D-Gal-1-Me was better than all other saccharide derivatives. This in contrast to β 3Gal-T1 and -T2 which had very low relative activities with disaccharides used as substrates (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-

galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998; Kolbinger, F., Streiff, M.B. and Ktopodis, A.G. Cloning of a human UDP-galactose:2-acetamido-2-deoxy-D-glucose β 3-galactosyltransferase catalysing the formation of type 1 chains. *J. Biol. Chem.* 273:433-440, 1998; Hennett, T., Dinter, A., Kuhnert, P., Mattu, T.S., Rudd, P.M. and Berger, E.G. Genomic cloning and expression of three murine UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase genes. *J. Biol. Chem.* 273:58-65, 1998). β 3Gal-T5 showed poor activity with saccharide derivatives representing N-linked core structures, namely β -D-GlcNAc-(1-6)- α -Man-1-Me, biantennary pentasaccharide and β -D-GlcNAc-(1-2)- α -D-Man. Particularly striking was a high relative activity towards β -D-GlcNAc(1-3)- α -D-GalNAc-1-*p*-Nph, which represents the core 3 O-linked structure. A comparison of relative activities of several β 3- and β 4Gal-transferases with core 3 and core 2 O-linked structures is presented in Table II.

Table II Activities with mucin-type core 2 and 3 acceptors

20		β GlcNAc-Bzl ^b		β GlcNAc(1,3) α GAlNAc- <i>p</i> -Nph		β GlcNAc(1,6)[β Gal(1,3)] α GAlNAc- <i>p</i> -Nph			
						0.2mM		2mM	
		nmol/min	nmol/min	nmol/min	nmol/min	nmol/min	nmol/min	nmol/min	nmol/min
	β 3Gal-T1 ^a	0.03	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)
	β 3Gal-T2	0.04	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)
25	β 3Gal-T5	0.1	0.3 (0.3)	0.2 (2.0)	0.2 (2.0)	0.0 (0.0)	0.0 (0.0)	0.01 (0.1)	0.01 (0.1)
	β 4Gal-T2	0.03	0.2 (0.6)	0.01 (0.3)	0.01 (0.3)	0.03 (1.0)	0.03 (1.0)	NA	NA
	β 4Gal-T3	0.03	0.1 (0.3)	0.03 (1.0)	0.03 (1.0)	ND	ND	ND	ND

^a Enzyme partially purified as described elsewhere herein.

^b β -D-GlcNAc-Bzl was used at 80mM with β 3Gal-T1 and β 3Gal-T2; at 20mM with β 3Gal-T5; at 0.25 mM with β 4Gal-T2 and at 2mM with β 4Gal-T3. ND, not determined. NA. not applicable due to inhibition. (), ratio between values obtained with core 2 or 3 and those obtained with β GlcNAc-Bzl.

None of the β 3Gal-Ts utilize the core 2 substrate and only β 3Gal-T5 catalyzed glycosylation of core 3 substrates. The two β 4Gal-Ts tested showed lower activity than β 3Gal-T5 with the core 3 substrate, however, direct comparison is not possible. Nevertheless, type 1 chain structures are found on core 3 (van Halbeek, H., Dorland, L., Vliegthart, J.F.G., et al. Primary-structure determination of fourteen neutral oligosaccharides derived from bronchial-mucus glycoproteins of patients suffering from cystic fibrosis, employing 500-MHz ^1H -NMR spectroscopy. *Eur J Biochem* 7-20, 1982), but to the best of our knowledge core 2 structures are always extended with type 2 chain N-acetyllactosamine chains.

Analysis of β 3Gal-Ts with glycoprotein acceptors (Table III) showed that β 3Gal-T5 only used bovine submaxillary mucin which carries approximately 10% GlcNAc terminating core 3 O-linked glycans (Mårtensson, S., Levery, S.B., Fang, T. and Bendiak, B. Neutral core oligosaccharides of bovine submaxillary mucin. Use of lead tetraacetate in the cold for establishing branch positions. *Eur. J. Biochem.* 258, 603-622, 1998).

Table III *Substrate specificity of β 3galactosyltransferases with glycoprotein acceptors*

	Acceptor substrate ^a	β 3Gal-T1		β 3Gal-T2		β 3Gal-T5	
		mmol/min		mmol/min		mmol/min	
20	β -D-GlcNAc-Bzl	0.03		0.04		0.1	
	Hen egg albumin	0.0	(0.0)	0.02	(0.5)	0.0	(0.0)
	Asialo-agalacto-fetuin	0.01	(0.3)	0.07	(1.8)	0.0	(0.0)
	Bovine submaxillary mucin	0.0	(0.0)	0.0	(0.0)	0.04	(0.4)
25	Orosomucoid	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)

* β -o-GlcNAc-Bzl was used at 80mM for β 3Gal-T1 and β 3Gal-T2 and at 20mM for β 3Gal-T5; (), ratio between values obtained with glycoproteins and those obtained with β -D -GlcNAc-Bzl.

As reported previously and in the present study β 3 Gal-T2 utilized glycoproteins with N-linked glycans while β 3Gal-T1 showed no or very low activity with glycoprotein acceptors (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol.*

Chem. 273:12770-12778, 1998) (Table III). A similar differential specificity for glycoproteins is found among β 4Gal-transferases, where β 4Gal-T1, -T2, and -T3 catalyze glycosylation of to N-linked glycoproteins, but a novel member, β 4Gal-T4, appears to be inactive with these substrates (Schwientek, T., Almeida, R., Lavery, S.B., Holmes, E., Bennett, E.P. and Clausen, H. Cloning of a novel member of the UDP-galactose: β -N-acetylglucosamine β 1,4- galactosyltransferase family, β 4Gal-T4, involved in glycosphingolipid biosynthesis. *J. Biol Chem.* 273:29295-29305, 1998).

Analysis of the catalytic activities with a panel of glycolipid substrates revealed that β 3Gal-T5 has high activity with GlcNAc β 1-3Gal β 1-4Glc β 1-Cer (Lc3), in either taurodeoxycholate or Triton CF-54 (Table IV).

Table IV Substrate specificities with glycolipid acceptors

		β 3Gal-T5 ^a		
5	Acceptor substrate		TDOC ^b	Triton CF-54
			$\mu\text{mol/h/mg}$	
10	GlcCer	(Glc β 1-Cer)	0.04	ND
	LacCer	(Gal β 1-4Glc β 1-Cer)	ND	ND
	Gb ₃	(Gal α 1-4Gal β 1-4Glc β 1-Cer)	ND	ND
	G β ₄	(GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-Cer)	0.6	0.09
	Gg ₃	(GalNAc β 1-4Gal β 1-4Glc β 1-Cer)	0.09	0.005
	GM ₂	(GalNAc β 1-4 (NeuAc α 2-3)Gal β 1-4Glc β 1-Cer)	ND	ND
	GM ₁	(Gal β 1-3GalNAc β 1-4(NeuAc α 2-3)Gal β 1-4Glc β 1-Cer)	ND	ND
15	Lc ₃	(GlcNAc β 1-3Gal β 1-4Glc β 1-Cer)	4.4	3.6
	nLc ₄	(Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1-Cer)	ND	ND
	nLC ₅	(GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1-Cer)	1.6	0.4

^a Enzyme partially purified as described elsewhere herein and the specific protein concentration was estimated by SDS-PAGE to be 300 $\mu\text{g/ml}$.

^b Assays were performed using 100 μg of taurodeoxycholate (TDOC) or Triton CF-54/100 μl of reaction mixture. ND, not detectable.

25 Activity was also found with nLc₅ but this was almost 3-fold lower than with Lc₃, and activity was significantly lower in Triton CF-54. Interestingly, considerable activity was observed with Gb₄ and there were detectable incorporation into GlcCer and Gg₃. The product formed with Gb₄ was characterized and found primarily to represent the expected Gal β 1-3Gb₄ structure. The apparent Km of β 3Gal-T5 for Lc₃Cer in the presence

30 taurodeoxycholate was approximately 2 μM , but due to substrate inhibition this result was only based on data points at low concentrations.

The acceptor substrate specificity and kinetic properties of β 3Gal-T5 are similar to a previously reported porcine tracheal β 3Gal-transferase activity (Sheares, B.T. and Carlson, D.M. Characterization of UDP-galactose:2-acetamido-2-deoxy-D- glucose 3 beta-galactosyltransferase from pig trachea. *J. Biol. Chem.* 258:9893-9898, 1983) and
 5 human colonic β 3Gal-transferase activity (Seko, A., Ohkura, T., Kitamura, H., Yonezawa, S., Sato, E. and Yamashita, K. Quantitative differences in GlcNAc:beta1-->3 and GlcNAc:beta1-->4 galactosyltransferase activities between human colonic adenocarcinomas and normal colonic mucosa. *Cancer Res* 56:3468-3473, 1996). Both the porcine and
 10 human β 3Gal-transferase activities have apparent Kms for UDP-Gal of 200-220 μ M using β GlcNAc β 1-3Gal(GalNAc) acceptor substrates, and the secreted recombinant β 3Gal-T5 had an apparent Km of 169 μ M (Table V).

Table V Kinetic properties of β 3Gal-T5

Substrate ^b	β 3Gal-T5 ^a	
	Km	Vmax
	mM	pmol/min
UDP-Gal	0.169	1422.2
β -D-GlcNAc-Bzl	20.4	873.4
β -D-GlcNAc-(1-3)- α -D-GalNAc-p-Nph	2.8	931.1
β -D-GlcNAc-(1-3)- α -D-Gal-Me	1.8	972.9

^a Enzyme partially purified as described elsewhere herein.

^b The concentrations used were 25-400 μ M for UDP-Gal, 3.75-60 mM for β -D-GlcNAc-Bzl and 0.3125-5 mM for β -D-GlcNAc-(1-3)- α -D-GalNAc-p-Nph and β -D-GlcNAc(1-3)- α -D-Gal-Me.

These relatively high Kms for donor substrates are significantly different from those reported for β 3Gal-T1 and -T2 (90 and 37 μ M, respectively) (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases:

characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998). Interestingly, activity of the full length coding construct of β 3Gal-T5 analyzed in Triton CF-54 homogenates of infected insect cells showed a lower apparent Km of 33 μ M for the donor substrate (not shown). The purified β 3Gal-transferase activity analyzed by Sheares, *et al.* (Shears, B.T. and Carlson, D.M. Characterization of UDP-galactose:2-acetamido-2-deoxy-D-glucose 3 beta-galactosyltransferase from pig trachea. *J. Biol. Chem.* 258:9893-9898, 1983) is, however, likely to represent a truncated proteolytically cleaved form that is often found with affinity-purified glycosyltransferase preparations (Clausen, H., White, T., Takio, K., et al. Isolation to homogeneity and partial characterization of a histo-blood group A defined Fuc alpha 1----2Gal alpha 1----3-N-acetylgalactosaminyltransferase from human lung tissue. *J. Biol. Chem.* 265:1139-1145, 1990). Moreover, Holmes (Holmes, E.H. Characterization and membrane organization of beta 1----3- and beta 1----4- galactosyltransferases from human colonic adenocarcinoma cell lines Cob 205 and SW403: basis for preferential synthesis of type 1 chain lacto-series carbohydrate structures. *Arch Biochem Biophys* 270:630-646, 1989) reported that non-purified β 3Gal-T activity from Colo205 cells had an apparent Km for UDP-Gal of 48 μ M using glycolipids as acceptor substrate. This preparation may contain both full and secreted forms of transferases. The recombinant full length form of β 3Gal-T5 resembled the recombinant secreted form in all other aspects tested. The porcine β 3Gal-transferase activity has an apparent Km for core 3 of 2.4 mM and β 3Gal-T5 exhibited an apparent Km for core 3 of 2.8 mM. Holmes (Holmes, E.H. Characterization and membrane organization of beta 1----3- and beta 1----4- galactosyltransferases from human colonic adenocarcinoma cell lines Cob 205 and SW403: basis for preferential synthesis of type 1 chain lacto-series carbohydrate structures. *Arch Biochem Biophys* 270:630-646, 1989) reported a Km for Lc₃Cer of 13 μ M for β 3Gal-T activity from Colo205 cells. The best substrate identified for β 3Gal-T5 was β -D-GlcNAc(1-3)-D- β -Gal-1-Me [apparent Km of 1.8 mM (Table V)]. This is similar to the apparent Km of 2.9 mM for human colonic β 3 Gal-T activity for β -D-GlcNAc(1-3)-D- β -Gal(1-4)-D- β -Glc (Seko, A., Ohkura, T., Kitamura, H., Yonezawa, S., Sato, E. and Yamashita, K. Quantitative differences in GlcNAc:beta1-->3 and GlcNAc:beta1-->4 galactosyltransferase activities between human colonic adenocarcinomas

and normal colonic mucosa. *Cancer Res* 56:3468-3473, 1996). β 3Gal-T5 showed strict donor substrate specificity for UDP-Gal and did not utilize UDP-GalNAc or UDPGlcNAc with the acceptor substrates tested (data not shown).

5 Expression of the full coding construct of β 3Gal-T5 in Sf9 cells 60 hours postinfection resulted in virtually all β 3Gal-transferase activity retained on cells (Table VI).

Table VI *Expression of full coding constructs of β 3Gal-T1 and β 3Gal-T5*

10	β 3Gal-T1 ^b		β 3Gal-T5	
	Cells	Media	Cells	Media
	<i>nmol/min/ml</i>		<i>nmol/min/ml</i>	
β -D-GlcNAc-	7.2	0.2	1.5	0.1

15 a β -D-GlcNAcBzl was used at 20mM.
b Enzyme sources were media or 1% Triton CF54 cell homogenates from β Gal-T1 and -T5 transfected Sf9 cells, harvested 60 hrs post-infection.

This was also found for β 3Gal-T1 (Table VI), and the same has been found
20 for the other β 3Gal-Ts as well as for a number of β 4Gal-Ts and polypeptide GalNAc-transferases (not shown). In contrast, more than 50 % of the enzyme activity is found in the media after 60 hours of transfection when truncated secreted constructs are used.

25 5.5. ¹H- and ¹³C-NMR SPECTROSCOPY OF PRODUCT FORMED GLYCOSYLATION OF CORE3-p-NPh WITH β 3GAL-T5

The product derived from reaction of β 3Gal-T5 with
GlcNAc β 1-3GalNAc α 1-lpNp was characterized by NMR spectroscopy to confirm that the proper linkage was formed between the donor sugar and the acceptor substrate.
30 Comparison of a 1-D ¹H-NMR spectrum of the product (Fig. 4) with that of the substrate (not shown) clearly showed an additional H-1 resonance (4.467 ppm) from a sugar residue linked in the β -configuration (³J_{1,2} = 7-9 Hz). This was accompanied by a downfield shift

of the β -GlcNAc H-1 resonance to 4.7 19 ppm ($\Delta\delta$ 0.065), as expected upon glycosylation of that residue. However, anomeric chemical shift criteria alone are insufficient for determining the identity and linkage position of the newly added residue. Since we were
5 unable to find NMR data for the para-nitrophenyl glycosides of either the Core 3 substrate or the expected Gal β 3Core 3 product in the literature or in glycoconjugate NMR databases, and since the substantial anisotropic effects of the paranitrophenyl group obviate direct comparison of chemical shift data with those of the benzylglycosides (Pollex-Kruger, A., Meyer, B., Stuike-Pill, R., Sinnwell, V., Matta, K.L. and Brockhausen, I. Preferred
10 conformations and dynamics of five core structures of mucin type O-glycans determined by NMR spectroscopy and force field calculations. *Glycoconjugate J* 10:365-380, 1993)).

15

20

25

30

Table VII ^1H , ^{13}C chemical shifts (ppm) and ^1H - ^1H coupling constants (Hz) for Core3-*p*-Nph substrate and biosynthetic Gal β 3-Core3-*p*-Nph product in D_2O at 25 °C.

5		Core 3		Gal β 1-3-Core3		
		GlcNAcB 3	GalNAc α	Gal β 3	GlcNAc β 3	GalNAc α
10	H-1 ^a	4.654	5.785	4.467	4.719	5.787
	H-2	3.734	4.502	3.525	3.866	4.505
	H-3	3.584	4.237	3.651	3.854	4.253
	H-4	3.488	4.291	3.919	3.589	4.303
	H-5	3.453	4.002	3.721	3.498	4.002
	H-6R	3.780	3.732	3.764	3.800	3.731
	H-6S	3.918	3.679	3.764	3.918	3.681
	H-8 (Me)	2.033	2.036	N.A. ^b	2.026	2.037
15	$J_{1,2}$	8.2	3.6	8.0	8.0	3.7
	$J_{2,3}$	10.2	11.3	10.3	N.F.O. ^c	10.9
	$J_{3,4}$	8.2	3.1	3.6	8.0	3.0
	$J_{4,5}$	9.8	<1.5	<1.5	10.1	<1.5
	$J_{5,6R}$	5.1	7.7	N.D. ^d	5.1	8.0
	$J_{5,6S}$	2.1	4.6	N.D.	2.2	4.4
	$J_{6R,6S}$	-12.3	-11.8	N.F.O.	-12.4	-11.7
20	C-1	102.33	95.51	103.24	101.99	95.48
	C-2	55.38	47.80	70.41	54.45	47.76
	C-3	73.17	75.88	72.31	81.86	76.01
	C-4	69.53	68.36	68.29	68.25	68.27
	C-5	75.48	71.63	75.10	74.94	71.61
	C-6	60.25	60.69	60.75	60.21	60.63
	C-7	174.28	173.61	N.A.	N.D.	N.D.
	(C=O) C-8 (Me)	21.99	21.76	N.A.	21.90	21.79

25 ^a chemical shifts are referenced to internal acetone (2.225 and 30.00 ppm for ^1H and ^{13}C , respectively).

^b N.A., not applicable.

^c N.F.O. non-first-order.

^d N.D., not determined.

30 Analysis of coupling constant data confirmed that the additional residue was a β -Gal ($^3J_{3,4}$ < 1.5 Hz). The 1-3 linkage was confirmed by the following criteria: (i) the largest glycosylation-induced chemical shift change among the core3 protons was observed

for β -GlcNAc H-3 ($\Delta\delta = 0.270$); (ii) consistent with this, in a ^1H - ^1H ROESY spectrum of the product (not shown), the strongest rotating frame Overhauser enhancement observed from β -Gal H-1 was to β -GlcNAc H-3; (iii) no other inter-residue correlations were
5 observed originating from β -Gal H-1, and no ambiguity is introduced into interpretation of the ROESY spectrum by the near degeneracy of β -GlcNAc H-2 and H-3 in the product, since there is no potential glycosylation site at C-2; (iv) comparison of ^{13}C spectral data for the substrate and product showed only one glycosylation-induced significant downfield shift, for β -GlcNAc C-3 ($\Delta\delta 8.69$). The magnitude of the ^{13}C shift change is essentially
10 diagnostic for glycosylation at that site.

The product formed with Gb_4 was characterized by 1-D ^1H -NMR spectroscopy (not shown); although more than one component was detected, five anomeric resonances were clearly observed for the major component, with chemical shifts and $^3J_{1,2}$ coupling constants virtually identical to those obtained previously for $\text{Gal}\beta 1\text{-}3\text{Gb}_4$
15 (Kannagi, R., Levery, S.B., Ishigami, F., et al. New globosides glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. *J. Biol. Chem.* 258:8934-8942, 1983). These were 4.810 ppm ($^3J_{1,2} = 3.6$ Hz), 4.620 ppm ($^3J_{1,2} = 8.7$ Hz), 4.267 ppm ($^3J_{1,2} = 7.4$ Hz), 4.198 ppm ($^3J_{1,2} = 7.9$ Hz), and 4.173 ppm ($^3J_{1,2} = 7.9$ Hz),
20 corresponding to H-1 of $\text{Gal}\alpha 4$, $\text{GalNAc}\beta 3$, $\text{Gal}\beta 4$, $\text{Gal}\beta 3$, and $\text{Glc}\beta 1$, respectively, of the $\text{Gal}\beta 1\text{-}3\text{Gb}_4$ sequence. Anomeric resonances from some unreacted Gb_4 were also detected in the product. The identity of a third, minor component, separable by preparative HPTLC, is currently under investigation.

25 5.6. NORTHERN ANALYSIS OF $\beta 3\text{GAL-T5}$

Northern analysis of multiple tissue northern (MTN) blots from Clontech failed to produce signals in several attempts. Sequence analysis suggested that the transcript could exceed 10 kilobase (kb), based on the finding that the first upstream polyadenylation consensus signal. Therefore, an absence of signal on the commercial blots
30 could be explained by poor transfer of large mRNAs. A blot was prepared with total RNA from human carcinoma cell lines, and care was taken to insure efficient transfer of long mRNA species. This yielded hybridizing bands at 12 kb or bigger for three cell lines:

AsPC-1, HPAF, Suit2, and S2-013. Interestingly, apart from the single EST identified for the coding region of β 3Gal-T5, no ESTs derived from any part of the 3'UTR of the approximate 10 kb region have been included in the EST databases. It is unclear at this time why this protein of average mass is encoded by a 12 kb mRNA transcript.

5.7. DNA, VECTORS, AND HOST CELLS FOR β 3GAL-T5

In practicing the present invention, many conventional techniques in molecular biology, microbiology, recombinant DNA, and immunology, are used. Such techniques are well known and are explained fully in, for example, Sambrook et al., 1989, *Molecular Cloning. A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *DNA Cloning: A Practical Approach*, Volumes I and II, 1985 (D.N. Glover ed.); *Oligonucleotide Synthesis*, 1984, (M.L. Gait ed.); *Nucleic Acid Hybridization*, 1985, (Hames and Higgins); *Transcription and Translation*, 1984 (Hames and Higgins eds.); *Animal Cell Culture*, 1986 (R.I. Freshney ed.); *Immobilized Cells and Enzymes*, 1986 (IRL Press); Perbal, 1984, *A Practical Guide to Molecular Cloning*; the series, *Methods in Enzymology* (Academic Press, Inc.); *Gene Transfer Vectors for Mammalian Cells*, 1987 (J. H. Miller and M. P. Carlos eds., Cold Spring Harbor Laboratory); *Methods in Enzymology* Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively); *Immunochemical Methods in Cell and Molecular Biology*, 1987 (Mayer and Waler, eds; Academic Press, London); Scopes, 1987, *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.) and *Handbook of Experimental Immunology*, 1986, Volumes I-IV (Weir and Blackwell eds.); Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manuals, © 1987-1997 Current Protocols, © 1994-1997 John Wiley and Sons, Inc.); and Dyson, N.J., 1991, Immobilization of nucleic acids and hybridization analysis, In: *Essential Molecular Biology: A Practical Approach*, Vol. 2, T.A. Brown, ed., pp. 111-156, IRL Press at Oxford University Press, Oxford, U.K.; each of which is incorporated by reference herein in its entirety).

The invention encompasses isolated nucleic acid fragments comprising all or part of the nucleic acid sequence disclosed herein as set forth in Figure 1. The fragments are at least about 8 nucleotides in length, preferably at least about 12 nucleotides in length,

and preferably at least about 15-20 nucleotides in length. Further, such fragments may be at least about 50, 100, 200, 500, 1000, 2000, 5000, or 10,000 nucleotides in length. The invention further encompasses isolated nucleic acids comprising sequences that are hybridizable under stringency conditions of 2X SSC, 55°C, to the sequence set fourth in
5 Figure 1; preferably, the nucleic acids are hybridizable at 2X SSC, 65°C; and most preferably, are hybridizable at 0.5X SSC, 65°C.

The nucleic acids may be isolated directly from cells. Alternatively, the polymerase chain reaction (PCR) method can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates .
10 Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

The nucleic acids of the present invention may be flanked by natural human
15 regulatory sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring
20 nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine,
25 etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoranlidate linkage. Furthermore, the nucleic acid sequences of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary
30 labels include radioisotopes, fluorescent molecules, biotin, and the like.

According to the present invention, useful probes comprise a probe sequence at least eight nucleotides in length that consists of all or part of the sequence from among

the sequences as set forth in Figure 1 or sequence-conservative or function-conservative variants thereof, or a complement thereof, and that has been labelled as described above .

The invention also provides nucleic acid vectors comprising the disclosed sequence or derivatives or fragments thereof. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression.

Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes . The inserted coding sequences may be synthesized by standard methods, isolated from natural sources, or prepared as hybrids, etc. Ligation of the coding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences may be achieved by known methods. Suitable host cells may be transformed/ transfected/infected as appropriate by any suitable method including electroporation, CaCl₂ mediated DNA uptake, fungal infection, microinjection, microprojectile, or other established methods.

Appropriate host cells included bacteria, archebacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. Of particular interest are *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, SF9 cells, C129 cells, 293 cells, *Neurospora*, and CHO cells, COS cells, HeLa cells, and immortalized mammalian myeloid and lymphoid cell lines. Preferred replication systems include M13, ColE1, SV40, baculovirus, lambda, adenovirus, and the like. A large number of transcription initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts . Examples of these regions, methods of isolation, manner of manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source of recombinantly produced β 3Gal-T5 derived peptides and polypeptides.

Advantageously, vectors may also include a transcription regulatory element (i.e., a promoter) operably linked to the β 3Gal-T5-coding portion. The promoter may optionally contain operator portions and/or ribosome binding sites. Non-limiting examples of bacterial promoters compatible with *E. coli* include: β -lactamase (penicillinase)

promoter; lactose promoter; tryptophan (trp) promoter; arabinose BAD operon promoter; lambda-derived P₁ promoter and N gene ribosome binding site; and the hybrid tac promoter derived from sequences of the trp and lac UV5 promoters. Non-limiting examples of yeast
5 promoters include 3-phosphoglycerate kinase promoter, glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter, galactokinase (GALI) promoter, galactose epimerase promoter, and alcohol dehydrogenase (ADH) promoter. Suitable promoters for mammalian cells include without limitation viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV).
10 Mammalian cells may also require terminator sequences and poly A addition sequences and enhancer sequences which increase expression may also be included; sequences which cause amplification of the gene may also be desirable. Furthermore, sequences that facilitate secretion of the recombinant product from cells, including, but not limited to, bacteria, yeast, and animal cells, such as secretory signal sequences and/or prohormone pro
15 region sequences, may also be included. These sequences are known in the art.

Nucleic acids encoding wild-type or variant polypeptides may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a cell, and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination--
20 based methods such as nonhomologous recombinations or deletion of endogenous genes by homologous recombination may also be used.

The nucleic acids of the present invention find use, for example, as probes for the detection of or related organisms and as templates for the recombinant production of peptides or polypeptides. These and other embodiments of the present invention are
25 described in more detail below.

5.8. POLYPEPTIDES OF β 3GAL-T5

The present invention encompasses isolated peptides (generally defined as a polypeptide having less than 50 amino acid residues) and polypeptides encoded by the
30 disclosed nucleic acid sequence. Peptides are preferably at least five residues in length. Peptides or polypeptides may be, for example, 6, 10, 15, 30, 50, 100, 200, or 300 residues in length.

Nucleic acids comprising protein-coding sequences can be used to direct the recombinant expression of polypeptides in intact cells or in cell-free translation systems. The known genetic code, tailored if desired for more efficient expression in a given host organism, can be used to synthesize oligonucleotides encoding the desired amino acid sequences. The phosphoramidite solid support method of Matteucci *et al.*, 1981, *J. Am. Chem. Soc.* 103:3185, the method of Yoo *et al.*, 1989, *J. Biol. Chem.* 264:17078, or other well known methods can be used for such synthesis. The resulting oligonucleotides can be inserted into an appropriate vector and expressed in a compatible host organism.

The polypeptides of the present invention, including function-conservative variants of the disclosed sequence, may be isolated from native or from heterologous organisms or cells (including, but not limited to, bacteria, fungi, insect, plant, and mammalian cells) into which a protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

Methods for polypeptide purification are well-known in the art, including, without limitation, preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For some purposes, it is preferable to produce the polypeptide in a recombinant system in which the protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against a protein or against peptides derived therefrom can be used as purification reagents. Other purification methods are possible.

The present invention also encompasses derivatives and homologues of polypeptides. For some purposes, nucleic acid sequences encoding the peptides may be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine); negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino acids.

The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

5.9. ANTIBODIES OF β 3GAL-T5

The present invention encompasses various antibodies that specifically recognize immunogenic components derived from β 3Gal-T5. Such antibodies can be used, for example, as reagents for detection and purification of β 3Gal-T5.

β 3Gal-T5 specific antibodies according to the present invention include polyclonal, monoclonal and humanized antibodies, as well as fragments and derivatives thereof. The antibodies of the invention may be elicited in an animal host by immunization with β 3 Gal-T5 components or may be formed by *in vitro* immunization of immune cells. The immunogenic components used to elicit the antibodies may be isolated from human cells or produced in recombinant systems. The antibodies may also be produced in recombinant systems programmed with appropriate antibody-encoding DNA. Alternatively, antibodies may be constructed by biochemical reconstitution of purified heavy and light chains. Antibodies of the invention include hybrid antibodies (i.e., containing two sets of heavy chain/light chain combinations, each of which recognizes a different antigen), chimeric antibodies (i.e., in which either the heavy chains, light chains, or both, are fusion proteins), and univalent antibodies (i.e., comprised of a heavy chain/light chain complex bound to the constant region of a second heavy chain). Also included are Fab fragments, including Fab' and F(ab)₂ fragments of antibodies, single chain antibodies, anti-idiotypic (anti-Id) antibodies, and epitope-binding antibody fragments. Methods for the production of all of the above types of antibodies and derivatives are well-known in the art. For example, techniques for producing and processing polyclonal antisera are disclosed in Mayer and Walker, 1987, *Immunochemical Methods in Cell and Molecular Biology*, (Academic Press, London). Further description of the polyclonal, monoclonal, chimeric and humanized antibodies of the invention is set forth below.

Polyclonal antibodies of the invention are heterogeneous populations of antibody molecules derived from the sera of immunized animals. Various procedures well

known in the art may be used for the production of polyclonal antibodies to β 3Gal-T5 and fragments thereof. For the production of polyclonal antibodies, various host animals can be immunized by injection with β 3Gal-T5 or a fragment or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies of the invention are homogeneous populations of antibodies to a particular antigen. A monoclonal antibody (mAb) to β 3Gal-T5 or a fragment or derivative thereof can be prepared by using any technique known in the art which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256, 495-497), and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4, 72), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAbs of use in this invention may be cultivated *in vitro* or *in vivo*.

Monoclonal antibodies of the invention include but are not limited to human monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (*e.g.*, Teng et al., 1983, Proc. Nat'l Acad. Sci. U.S.A. 80, 7308-7312; Kozbor et al., 1983, Immunology Today 4, 72-79; Olsson et al., 1982, Meth. Enzymol. 92, 3-16).

This invention provides chimeric antibodies specific for β 3Gal-T5 or a fragment or derivative thereof. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Various techniques are available for the production of such chimeric antibodies (*see, e.g.*, Morrison

et al., 1984, Proc. Nat'l Acad. Sci. U.S.A. 81, 6851-6855; Neuberger et al., 1984, Nature, 312, 604-608; Takeda et al., 1985, Nature, 314, 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity.

This invention provides humanized antibodies specific for β 3Gal-T5 or a fragment or derivative thereof. Briefly, humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. Various techniques have been developed for the production of humanized antibodies (*see*, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety). An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarily determining regions (CDRs). The extent of the framework region and CDRs have been precisely defined (*see*, Kabat et al., 1983, Sequences of proteins of immunological interest, U.S. Department of Health and Human Services).

Further, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, 1988, Science 242, 423-426; Huston et al., 1988, Proc. Nat'l. Acad. Sci. U.S.A. 85, 5879-5883; and Ward et al., 1989, Nature 334, 544-546) can be adapted to produce single chain antibodies specific for β 3Gal-T5 or a fragment or derivative thereof. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region together via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes of β 3Gal-T5 or a fragment or derivative thereof may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246, 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

30

Further, general methods of antibody production and use are suitable for the antibodies of the invention. For example see Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, which is incorporated herein by reference in its entirety.

The antibodies of the invention can be purified by standard methods, including but not limited to preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. Purification methods for antibodies are disclosed, e.g., in *The Art of Antibody Purification*, 1989, Amicon Division, W.R. Grace & Co. General protein purification methods are described in *Protein Purification: Principles and Practice*, R.K. Scopes, Ed., 1987, Springer-Verlag, New York, New York.

Anti- β 3Gal-T5 antibodies, whether unlabeled or labeled by standard methods, can be used as the basis for immunoassays. The particular label used will depend upon the type of immunoassay used. Examples of labels that can be used include, but are not limited to, radiolabels such as ^{32}P , ^{125}I , ^3H and ^{14}C ; fluorescent labels such as fluorescein and its derivatives, rhodamine and its derivatives, dansyl and umbelliferone; chemiluminescers such as luciferia and 2,3-dihydrophthal-azinediones; and enzymes such as horseradish peroxidase, alkaline phosphatase, lysozyme and glucose-6-phosphate dehydrogenase.

The antibodies can be tagged with such labels by known methods. For example, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bisdiazotized benzadine and the like may be used to tag the antibodies with fluorescent, chemiluminescent or enzyme labels. The general methods involved are well known in the art and are described in, e.g., Chan (Ed.), 1987, *Immunoassay: A Practical Guide*, Academic Press, Inc., Orlando, FL.

The invention described and claimed herein can be further appreciated by one skilled in the art through reference to the examples which follow. These examples are provided merely to illustrate several aspects of the invention and shall not be construed to limit the invention in any way.

6. EXAMPLES

Using BLAST analysis of an EST database, we identified a total of ten candidate human homologous members of the β 3Gal-T gene family including the four members previously reported (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998). Analysis of sequence similarity of the first four members revealed features indicative of functions of encoded enzymes, including conservation of cysteine residues, spacing of conserved motifs, and hydropathy profiles (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998). β 3Gal-T4 differed significantly from β 3Gal-T1, -T2, and -T3 in this respect, and the function of this enzyme was different in that the acceptor saccharide was β GalNAc in ganglioseries glycolipids (Miyaki, H., Fukumoto, S., Okada, M., Hasegawa, T. and Furukawa, K. Expression cloning of rat cDNA encoding UDP-galactose G(D2) β 1,3 galactosyltransferase that determines the expression of G(D1 b)/G(M 1)G(A1). *J. Biol. Chem.* 272:24794-24799, 1997; Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterisation of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998).

A sequence derived from an EST clone (GenBank accession number AJ003597) was predicted to represent a new gene encoding a β 3Gal-T forming the Gal β 1-3GlcNAc linkages. This report describes the cloning and expression of this gene, designated β 3Gal-T5, and demonstrates that the encoded enzyme has better kinetic properties than those of the previously cloned β 3Gal-Ts. β 3Gal-T5 is a candidate for the β 3Gal-T activity found in epithelia.

6.1. IDENTIFICATION AND CLONING OF β 3Gal-T5

The BLASTn and tBLASTn were used with the coding sequence of human β 3Gal-T2 to search the dbEST database at The National Centre for Biotechnology

Information (NCBI, USA) as previously described (Almeida, R., Amado, M., David, L., et al. A Family of Human β 4-Galactosyltransferases: Cloning and expression of two novel UDP-Galactose β -N-Acetylglucosaminase β 1,4-Galactosyltransferases, β 4Gal-T2 and β 4Gal-T3. *J.Biol.Chem.* 272:31979-31992, 1997). One EST (GenBank accession number
5 AJ003597) was identified as representing a putative novel β 3Gal-T gene. Since the coding regions of all other cloned members of the human β 3Gal-T gene family were found to be encoded in a single exon, we used the EST sequence information to design primers for PCR screening of a P1 genomic library. A human foreskin P1 library (DuPont Merck
10 Pharmaceutical Company Human Foreskin Fibroblast P1 Library) was screened using the primer pairs EBER 1301 (5'-CTTCCTTAAGCTCCCAGATAC 3') (SEQ ID NO:1) and EBER 1302 (5'- GTTTCCGCTGCACTGCTGGTG 3') (SEQ ID NO:2). One P1 clone for β 3Gal-T5 (DMPC-HFF#1-1195h3) as well as DNA from P1 phages were obtained from Genome Systems Inc. Sequencing of this P1 DNA revealed an open reading frame of 933
15 bp encoding a putative protein with a type II domain structure (Fig. 1). The entire coding sequence of β 3Gal-T5 was fully sequenced using automated sequencing (ABI377, Perkin Elmer) with dye terminator chemistry. The EST clone AJ003597 was derived from a chromosome 21 library, and subsequently a 165 kilobase pair PAC sequence containing the entire sequence of β 3Gal-T5 was linked to 21 q22.3 (GenBank accession number-
20 AF064860). The EST sequence did not appear to be derived from correct oligo-dT priming, and analysis of the genomic PAC sequence showed that the first downstream consensus polyadenylation signal (AATAAA) was 9568 bp from the first initiation codon. The putative 3' UTR sequence contained repeats and potential short coding regions, but none of the coding regions showed similarity to known genes. No ESTs from the 3'UTR have been
25 deposited in the GenBank database. A second consensus polyadenylation signal is found 2991 bp downstream of the first, and a few 3' ESTs have been identified from this site and mapped (STS-N41029), but no sequence encoding protein with similarity to known genes have been assigned from this region.

The EST sequence (AJ003597) is 338 nucleotides long. Nucleotides 1-312
30 of AJ003597 encode the complement of nucleotides 38-349 of the coding region of β 3Gal-T5 (Figure 1) (nucleotides 116-427 of SEQ ID NO:8).

6.2. EXPRESSION OF β 3Gal-T5

What follows are examples of expression of β 3Gal-T5 in insect cells, and as a full-length or partial-length (soluble) gene product in CHO cells.

5

6.2.1. EXPRESSION OF β 3Gal-T5 IN INSECT CELLS

An expression construct (pAcGP67- β 3Gal-T5-sol) designed to exclude the hydrophobic transmembrane segment and to encode amino acid residues 25-310, was prepared by PCR using P1 genomic DNA, and the primer pair EBER1300 sol (5'-ATGTACAGTCTAAATCCTTTC) (SEQ ID NO:3) and EBER1310 (5'-TCAGACAGGCGGACAATCTTC) (SEQ ID NO:4) (Fig. 1), which included *Bam*HI restriction sites. PCR product was cloned into the *Bam*HI site of pAcGP67B (Pharmingen). An expression construct (pVL- β 3Gal-T5-full) designed to encode the full coding sequence (from first ATG, Fig. 1) was prepared by PCR with P1 genomic DNA using the primer pair EBER1309 (5'-ATGGCTTCCCGAAGATGAG) (SEQ ID NO:5) and EBER1310. This PCR product was cloned into the *Bam*HI site of pVL1193 (Pharmingen). Both soluble and full length constructs were fully sequenced to confirm fidelity. Plasmids pAcGP67- β 3GalT5-sol and pVL- β 3Gal-T5-full were co-transfected with Baculo-Gold™ DNA (Pharmingen) as described previously (Bennett, E.P., Hassan, H. and Clausen, H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetyl-galactosaminyl-transferase, GaINAc-T3. *J. Biol. Chem.* 271:17006-17012, 1996). Recombinant Baculo-virus were obtained after two successive amplifications in Sf9 cells grown in serum-containing medium, and titers of virus were estimated by titration in 24-well plates with monitoring of enzyme activities. Controls included pAcGP67- β 3Gal-T1 (Amado, M., Almeida, R., Carneiro, F., et al. A family of human β 3-galactosyltransferases: characterization of four members of a UDP-galactose β -N-acetylglucosamine/ β -N-acetylgalactosamine β 1,3-Galactosyltransferase family. *J. Biol. Chem.* 273:12770-12778, 1998), pAcGP67- β 3Gal-T2 (Id.), pAcGP67- β 4Gal-T2 (Almeida, R., Amado, M., David, L., et al. A Family of Human β 4-Galactosyltransferases: Cloning and expression of two novel UDP-Galactose β -N-Acetylglucosamine β 1,4-Galactosyltransferases, β 4Gal-T2 and β 4Gal-T3. *J. Biol. Chem.* 272:31979-31992, 1997), pAcGP67- β 4Gal-T3 (Id.), and pAcGP67-GaINAc-T3-sol (Bennett, E.P., Hassan, H. and

Clausen, H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetyl-galactosaminyl-transferase, GalNAc-T3. *J. Biol. Chem.* 271:17006-17012, 1996). For large scale expression amplified virus was used to infect High Five™ cells grown in serum-free media (Invitrogen) in upright roller bottles shaking at 140 rpm and 27°C.

The kinetic properties were determined with partially purified, secreted forms of the enzymes. Semipurification of enzymes from serum-free medium of infected High-Five™ cells was performed by sequential Amberlite, DEAE-Sephacel and 5-Sephadex chromatography as described previously (Wandall, H.H., Hassan, H., Mirgorodskaya, E., et al. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide Nacetyl-galactosaminyltransferase family, GalNAc-T1, -T2, and -T3. *J. Biol. Chem.* 272:23503-23514, 1997). Comparisons of enzymes were performed relatively to the activity obtained with β GlcNAc-Bzl (Tables II and III). Full length enzymes were assayed with 1% Triton CF54 homogenates of washed cells. Enzyme assays were performed in 50 μ l total reaction mixtures containing 25 mM Cacodylate (pH 7.5), 10 mM $MnCl_2$, 0.25% Triton X-100, 100 μ M UDP-[^{14}C]-Gal (2,600 cpm/nmol) (Amersham), and varying concentrations of acceptor substrates (Sigma) (see Table I for structures). Reaction products were quantified by Dowex-1 chromatography. Assays with glycoproteins were performed with the standard reaction mixture modified to contain 150 μ M UDP-Gal, 54 mM NaCl, and 0.5 mg ovalbumin, asialo-agalacto-fetuin, orosomucoid, or bovine submaxillary mucin acceptor substrates obtained as previously described (Schwientek, T., Almeida, R., Levery, S.B., Holmes, E., Bennett, E.P. and Clausen, H. Cloning of a novel member of the UDP-galactose: β -N-acetylglucosamine β 1,4-galactosyltransferase family, β 4Gal-T4, involved in glycosphingolipid biosynthesis. *J. Biol. Chem.* 273:29295-29305, 1998). The transfer of Gal was evaluated after acid precipitation by filtration through Whatman GF/C glass fibre filters. Assays to determine K_m of acceptor substrates and donor substrates were modified to include 200 μ M UDP-[^{14}C]-Gal (2,600 cpm/nmol) or 30mM GlcNAc β -benzyl. Assays with glycolipid acceptors were conducted as previously described (Holmes, E.H. Characterization and membrane organization of β 1-3- and β 1-4- galactosyltransferases from human colonic adenocarcinoma cell lines Cob 205 and SW403: basis for preferential synthesis of type 1

chain lacto-series carbohydrate structures. *Arch Biochem Biophys* 270:630-646, 1989) in reaction mixtures containing 2.5 μ mol HEPES buffer, pH 7.2, 1 μ mol $MnCl_2$, 100 μ g taurodeoxycholate or Triton CF-54, 20 μ g acceptor glycolipid, 15 nmol UDP-[^{14}C]-galactose (13,000 cpm/nmol) and enzyme in a total volume of 100 μ l. Conditions for
5 incubation and product isolation were as previously described (Id.).

6.2.2. STABLE EXPRESSION OF FULL CODING SEQUENCE OF β 3Gal-T5 IN CHO CELLS

10 A cDNA sequence encoding the full coding sequence of the β 3Gal-T5 gene was derived by RT-PCR using primers EBER 1309 and EBER 1310 with *Bam*HI restriction sites introduced. The PCR product was designed to yield a β 3Gal-T5 protein with a hydrophobic transmembrane retention signal in order to have the enzyme expressed and positioned in the appropriate Golgi compartment of the transfected cell. The PCR product
15 was inserted into the *Bam*HI site of a mammalian expression vector pCDNA3 (Invitrogen), and the construct, pCDNA3- β 3Gal-T5-mem, was transfected into CHO cells and stable transfectants were selected. Further details are provided below.

The full-length Golgi-retained form of β 3Gal-T5 was stably expressed in Chinese Hamster Ovary cells (CHO-K1) obtained from ATCC. The full-length coding
20 construct, designed to contain amino acids 1-310, was prepared by PCR with P1 genomic DNA using the primer pair EBER1309 and EBER1310 (Fig. 1), which included *Bam*HI restriction sites. Correct insertion of the PCR product cloned into the *Bam*HI site of the pCDNA3 vector (Invitrogen) was confirmed by sequencing. The predicted coding region of the construct is shown in Figure 1. CHO-K1 cells were transfected using 0.2 μ g DNA and 5
25 μ g lipofectamine (Invitrogen) in subconfluent 6 well plates according to the manufacturer's protocol. After 48 hours, the medium was changed and 400 μ g/ml G418 was added. At 72 hours 10-20 % of the wells were trypsinized and the percentage of cells expressing β 3Gal-T5 was evaluated by immunocytology using an anti- β 3Gal-T5 monoclonal antibody, UH9.

30 6.2.3. STABLE EXPRESSION OF SOLUBLE FORM OF β 3Gal-T5 IN CHO CELLS

cDNA pAcGP67- β 3Gal-T5-sol containing the coding sequence of a soluble, secreted β 3Gal-T5 enzyme was cloned into the *Bam*HI site of a modified mammalian expression vector, pCDNA3 (Invitrogen). pCDNA3 was modified by insertion of an
 5 interferon signal peptide sequence into the *Kpn*I/*Bam*HI site of ensuring secretion of the expressed product when cloned into the vector. The pCDNA3- γ INF- β 3Gal-T5-sol construct was transfected into CHO cells and stable transfectants were selected. Further details are provided below.

The secretable form of β 3Gal-T5 was stably expressed in Chinese Hamster
 10 Ovary cells (CHO-K1) obtained from ATCC. A truncated construct, designed to contain amino acids 25-310, was prepared by PCR using P1 genomic DNA and the primer pair EBER1300 sol (SEQ ID NO:3) and EBER1310 (SEQ ID NO:4) (Fig. 1), which included *Bam*HI restriction sites. The PCR product was cloned into the *Bam*HI site of a modified pCDNA3 vector (Invitrogen). The pCDNA3 vector was modified to include 19 amino acids
 15 of the gamma-interferon signal sequence by directional insertion of a synthetic sequence of 91 bp coding for the interferon sequence with *Kpn*I and *Bam*HI flanking sites. The modified pCDNA3 vector was constructed as follows. Four synthetic oligonucleotides were synthesized: INFFOR (5'-cggggtaccggaacgatgaaatatacaag-3') (SEQ ID NO:14); INFREVA (5'-ggcggatccaggcagatcacagccaagagaacccaaaacg-3') (SEQ ID NO:15); INFREVB (5'-
 20 gcgatcccaggcagatcacagccaagagaacccaaaacg-3') (SEQ ID NO:16); and INFREVC (5'-gcgatcccaggcagatcacagccaagagaacccaaaacg3') (SEQ ID NO:17). Oligonucleotide primer pairs INFFOR/INFREVA, INFFOR/INFREVB and INFFOR/INFREVC were used to PCR amplify an interferon coding DNA fragment from human genomic DNA under the following conditions: 95°C for 30 seconds, 60°C for 5 seconds, 72°C for 15 seconds, using
 25 Ampli-Taq (Perkin-Elmer Cetus) and a model 480 Thermocycler (Perkin-Elmer). The use of three 3' primers spaced one base apart yields three vectors with a *Bam*HI site positioned for any of three reading frames with respect to the signal sequence.

CHO-K1 cells (ATCC) were transfected using 0.2 μ g DNA and 5 μ g lipofectamine (Invitrogen) in subconfluent 6 well plates according to the manufacturer's
 30 protocol. After 48 hours, the medium was changed and 400 μ g/ml G418 was added. At 72 hours 10-20 % of the wells were trypsinized and the percentage of cells expressing β 3Gal-T5 was evaluated by immunocytology using an anti- β 3Gal-T5 monoclonal antibody, UH9.

6.3. CHARACTERIZATION OF THE PRODUCT FORMED WITH CORE3-p-Nph BY β 3Gal-T5

Complete glycosylation of core3-p-Nph was performed in a reaction mixture consisting of 1 mU β 3Gal-T5 (specific activity determined with β GlcNAc-Umb), 2 mg core3-p-Nph, 50 mM Tris (pH 7.0), 1 mM MnCl_2 , 0.01 % Triton X-100, and 4.6 μmol UDP-Gal in a final volume of 500 μl . The glycosylation was monitored by HPTLC and was complete after 3 hours incubation. The reaction product was isolated as previously described on octadecyl-silica cartridges ("Bakerbond;" J.T. Baker, Phillipsburg, N.J.) (Almeida, R., Amado, M., David, L., et al. A Family of Human β 4-Galactosyltransferases: Cloning and expression of two novel UDP-Galactose β -N-Acetylglucosamine β 1,4-Galactosyltransferases, β 4Gal-T2 and β 4Gal-T3. *J.Biol.Chem.* 272:31979-31992, 1997) using successive stepwise elutions with MeOH. The MeOH solution was evaporated to dryness and subjected to ^1H -NMR analysis as described below.

6.3.1. 1-D ^1H -NMR SPECTROSCOPY OF REACTION PRODUCTS

WITH CORE3-p-Nph AND Gb₄

The purified product from reaction with core3-p-Nph was deuterium exchanged by repeated sonication and lyophilization from D_2O . A saturated solution in D_2O was used for NMR analysis. 1-D ^1H -NMR, 2-D ^1H - ^1H -TOCSY (Braunschweiler, L. and Ernst, R.R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. *J. Magn. Reson.* 53:521-528, 1983; Bax, A. and Davis, D.G. MLEV-1 7-based two-dimensional homonuclear magnetization transfer spectroscopy. *J. Magn. Reson.* 65:355-360, 1985a) and -ROESY (Bothner-By, A.A., Stephens, R.L., Lee, J.M., Warren, C.D. and Jeanloz, R.W. Structure determination of a tetrasaccharide: Transient nuclear Overhauser effects in the rotating frame. *J.Am. Chem. Soc* 106:811-813, 1984; Bax, A. and Davis, D.G. Practical aspects of two-dimensional transverse NOE spectroscopy. *J. Magn. Reson.* 63:207-213, 1985b) experiments were performed at 298 °C on a Varian Unity Inova 600 MHz spectrometer (0.5 mL in 5 mm tube) using standard acquisition software available in the Varian VNMR software package. A ^1H -detected, ^{13}C -decoupled, phase sensitive, gradient (Davis, A.L., Keeler, J., Laue, E.D. and Moskau, D. Experiments for recording pure-absorption heteronuclear correlation spectra using pulsed field gradients. *J. Magn.*

Reson. 98:207-216, 1992) ^{13}C - ^1H -HSQC (Bodenhausen, G. and Ruben, D.J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy. *Chem. Phys. Lett.* 69:185-189, 1980) experiment was performed at 298°C on a Varian Unity Inova wide bore 500 MHz spectrometer (2 mL in 8 mm tube). A 2 mg sample of core3-pNph was prepared in similar fashion and analyzed under identical conditions for comparison. Chemical shifts are referenced to internal acetone (2.225 and 29.92 ppm for ^1H and ^{13}C , respectively).

The purified glycosphingolipid products from reaction with Gb₄ were deuterium exchanged by dissolving in CDCl_3 - CD_3OD 2:1, evaporating thoroughly under dry nitrogen (repeating 2x), and then dissolved in 0.5 mL $\text{DMSO}-d_6/2\% \text{D}_2\text{O}$ (Dabrowski, J., Hanfland, P. and Egge, H. Structural analysis of glycosphingolipids by high resolution ^1H nuclear magnetic resonance spectroscopy. *Biochemistry* 19:5652-5658, 1980) for NMR analysis. 1-D ^1H -NMR spectra were acquired at 600 MHz (temperature, 308°K); 10,000 FIDs were accumulated, with solvent suppression by presaturation pulse during the relaxation delay. Spectra were interpreted by comparison to spectra of relevant glycosphingolipid standards acquired previously under comparable conditions (Dabrowski, J., Hanfland, P. and Egge, H. Structural analysis of glycosphingolipids by high resolution ^1H nuclear magnetic resonance spectroscopy. *Biochemistry* 19:5652-5658, 1980; Kannagi, R., Lavery, S.B., Ishigami, F., et al. New globosides glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. *J. Biol. Chem.* 258:8934-8942, 1983).

6.4. RESTRICTED ORGAN EXPRESSION PATTERN OF $\beta 3\text{Gal-T5}$

Total RNA was isolated from human adenocarcinoma cell lines AsPC-1, BxPC-3, Capan-1, Capan-2, Colo357, HPAF, HT-29, PANC-1, Suit2, and S2-013 as described previously (Sutherlin, M.E., Nishimori, I., Caffrey, T., et al. Expression of three UDP-N-acetyl-alpha-D galactosamine:polypeptide GalNAc N-acetylgalactosaminyl-transferases in adenocarcinoma cell lines. *Cancer Res* 57:4744-4748, 1997). Twenty five μg of total RNA was subjected to electrophoresis on a 1 % denaturing agarose gel and transferred to nitrocellulose as described previously (Sutherlin, M.E., Nishimori, I., Caffrey, T., et al. Expression of three UDP-N-acetyl-alpha-D galactosamine:polypeptide GalNAc N-

acetylgalactosaminyltransferases in adenocarcinoma cell lines. *Cancer Res* 57:4744-4748, 1997). Human Multiple Tissue northern blots, MTNI and MTNII, were obtained from Clontech. The soluble expression construct was used as probe. The probe was labeled by random priming using $\alpha P^{32}dCTP$ (Amersham) and an oligo labeling kit (Pharmacia). The blots were probed overnight at 42 °C as previously described (Bennett, E.P., Hassan, H. and Clausen, H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetyl-galactosaminyl-transferase, GaINAc-T3. *J. Biol. Chem.* 271:17006-17012, 1996), washed 2 x 10 min at RT with 2 x SSC, 1% $Na_4P_2O_2$, 2 x 20 min at 65 °C with 0.2 x SSC, 1 % SDS, 1% $Na_4P_2O_2$ and once 10 min with 0.2 x SSC at RT ("preferred hybridization conditions").

6.5. ANALYSIS OF DNA POLYMORPHISM OF THE $\beta 3Gal-T5$ GENE

Primer pairs EBER 1320 (5'-CAGCGAGGTTCTAGAGTTTCC-3') (SEQ ID NO:6) and EBER 1321 (5'-GAAATCCACGCCAGAATGTCG-3') (SEQ ID NO:7) for amplification of the entire coding sequence have been used for PCR amplification of exon 1. The PCR product was subcloned and the sequence of 10 clones containing the appropriate insert was determined assuring that both alleles of each individual are characterized.

6.6. ANTIBODIES TO $\beta 3Gal-T5$

An anti- $\beta 3Gal-T5$ monoclonal antibody, UH9, was prepared by immunizing mice with a purified $\beta 3Gal-T5$ preparation that gave a single band of approximately 35,000 on SDS-PAGE Coomassie stained gel. Balb/c mice were immunized with one subcutaneous or intraperitoneal injection of 10 μl undernaturated protein in Freund's complete adjuvant, followed by two injections with Freund's incomplete adjuvant, and finally an intravenous booster without adjuvant. Eyebleeds were taken 7 days after third immunization, and the titer and specificity of anti- $\beta 3Gal-T5$ antibodies was evaluated. Fusion to NS-1 and the cloning procedure was as described in White et al., *Biochemistry* 29:2740 (1990). The monoclonal antibody UH9 was selected for reactivity with unfixed cells and/or tissues, as well as ability to immunoprecipitate $\beta 3Gal-T5$ activity. Hybridomas were selected by three criteria: (i) differential reactivity in ELISA assays with purified

recombinant enzymes; (ii) immunocytology on Sf9 cells two days after infection with Baculovirus containing β 3Gal-transferases, β 3Gal-T1, -T2, -T3, -T4, and -T5; and (iii) differential immunoprecipitation of active recombinant enzymes.

5 ELISA analysis was performed as described by White et al. (Id.), using purified recombinant β 3Gal-T1, -T2, and -T5, using an initial antigen concentration of 10 μ g/ml.

The immunocytology assay was performed by washing trypsinized cells twice in PBS and air drying the washed cells onto coverslips. Dried slides were fixed in 100% ice cold acetone for 10 min, dried, and incubated with monoclonal anti- β 3Gal-T5
10 antibody for 1 hour. After washing with PBS, slides were incubated with FITC-conjugated rabbit anti-mouse IG for 30 minutes, washed with PBS and mounted in glycerol and analyzed by microscopy.

Immunoprecipitation of recombinant human β 3Gal-transferases was performed as follows. Secreted forms of human β 3Gal-transferases were expressed in Sf9
15 cells and media were harvested three days post-infection and used as enzyme source. Protein G Sepharose was saturated sequentially with rabbit anti-mouse IgG and monoclonal antibodies as culture supernatants. A 5% suspension of Protein G beads was added to Sf9 medium containing either GalNAc-T1, -T2, -T3 or -T4. After incubation for 1 hour at 4
20 degrees C, beads were washed in PBS, and resuspended in 25 mM Tris (pH 7.4), 0.25% Triton X-100. β 3Gal-transferase activities were measured in the supernatants and the washed pellets. UH9 selectively immunoprecipitated β 3Gal-T5 activity but not β 3Gal-T1 or -T2 activity.

Western blot analysis with purified recombinant enzymes was also performed. It proved difficult to select antibodies reactive with both the native and the
25 denatured β 3Gal-T5 enzyme. The antibody UH9 is therefore likely to be directed to a conformational epitope, and to detect the native conformation of β 3Gal-T5. Another antibody, designated UH10, only reacted with denatured β 3Gal-T5 as evidenced by ability to western blot. This antibody did stain insect cells infected with pVL- β 3Gal-T5-full and
30 pAcGP67- β 3Gal-T5-sol, but it did not stain CHO cells stably transfected with the β 3Gal-T5 expression constructs or various epithelial cell lines and tissues. Furthermore, UH10 did not immunoprecipitate β 3Gal-T5 enzyme activity.

To correlate immunoreactivity with enzyme activity, transfected cells expressing soluble β 3Gal-T5 were trypsinized and plated in 96 well plates. Two rounds of screening and cloning by limiting dilution using immunoreactivity with UH9 were performed and clones achieving over 50 % positive cells were selected and tested for level of secreted enzyme in supernatant of confluent cultures. The intensity of immunoreactivity by the cytology assay correlated in all cases with level of β 3Gal-T5 enzyme activity found in spent media from clones.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed since these embodiments are intended as illustration of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Throughout this application various references are cited, the contents of each of which is hereby incorporated by reference into the present application in its entirety.

20

25

30

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding UDP- galactose: β - *N*-acetylglucosamine β 1, 3-galactosyltransferase (β 3Gal-T5).
5
2. The isolated nucleic acid as defined in claim 1, wherein said nucleic acid is DNA.
3. The isolated nucleic acid as defined in claim 2, wherein said DNA is cDNA.
10
4. An isolated nucleic acid as defined in claim 2, wherein said DNA is genomic DNA.
5. An isolated nucleic acid as defined in claim 1, wherein said nucleic acid
15 comprises the nucleotide sequence of nucleotides 1-930 as set forth in Figure 1 or sequence-conservative or function-conservative variants thereof.
6. An isolated nucleotide sequence comprising nucleotides 73-930 as set forth
in Figure 1.
20
7. An isolated nucleotide sequence comprising nucleotides selected from the group consisting of nucleotides 1-200; nucleotides 201-400; nucleotides 401-600; nucleotides 601-800; and nucleotides 801-930 of claim 1 that hybridizes to a nucleic acid under stringent conditions.
25
8. An isolated nucleic acid which hybridize under conditions of high stringency with the nucleic acid having the sequence of nucleotides 1-930 as set fourth in Figure 1.
9. A nucleic acid vector comprising a nucleic acid sequence encoding β 3Gal-T5 or fragments thereof.
30

10. A vector as defined in claim 9, wherein said sequence comprises the nucleotide sequence of nucleotides 1-930 as set forth in Figure 1 or sequence-conservative or function-conservative variants thereof.

5 11. The vector as defined in claim 10, wherein said sequence encoding β 3Gal-T5 is operably linked to a transcriptional regulatory element.

12. A nucleic acid vector comprising the nucleotide sequence of claim 5.

10 13. A nucleic acid vector comprising the nucleotide sequence of claim 6.

14. A host cell comprising a vector as defined in claim 9.

15 15. A host comprising a vector as defined in claim 11, wherein said cell is stably transfected with said vector.

16. The host cell as defined in claim 14, wherein said cell is stably transfected with said vector.

20 17. The host cell as defined in claim 13, wherein said cell produces enzymatically active β 3Gal-T5.

25 18. The host cell as defined in claim 13, wherein said cell is selected from the group consisting of bacterial, yeast, insect, avian, and mammalian cells.

19. The host cell as defined in claim 17, wherein said cell is selected from the group consisting of bacterial, yeast, insect, avian, and mammalian cells.

30 20. A cell as defined in claim 19, wherein said cell is Sf9.

21. A cell as defined in claim 19, wherein said cell is CHO.

22. A host cell comprising the nucleic acid vector of claim 12.
23. A host cell comprising the nucleic acid vector of claim 13.
- 5 24. A method for producing β 3Gal-T5 polypeptides, which comprises:
- (i) introducing into a host cell an isolated DNA molecule encoding a human β 3Gal-T5, or a DNA construct comprising a DNA sequence encoding β 3Gal-T5;
 - 10 (ii) growing the host cell under conditions suitable for human β 3Gal-T5 expression; and
 - (iii) isolating β 3Gal-T5 produced by the host cell.
25. An isolated UDP- galactose: β - *N*-acetylglucosamine β 1, 3-
galactosyltransferase (β 3Gal-T5) polypeptide.

15

20

25

30

AMENDED CLAIMS

[received by the International Bureau on 03 April 2000 (03.04.00);
original claims 1-21, 24 and 25 amended; new claims 26-37 added;
remaining claims unchanged (5 pages)]

1. An isolated nucleic acid of less than 10,000 nucleotides or a
5 complement thereof comprising a nucleotide sequence encoding UDP-galactose: β -N-acetylglucosamine β 1,3galactosyltransferase (β 3Gal-T5) (SEQ ID NO:9).
2. The isolated nucleic acid of claim 1 which is DNA.
- 10 3. The isolated DNA of claim 2 which is cDNA or genomic DNA.
4. The isolated nucleic acid of claim 1 which is RNA.
5. An isolated nucleic acid of less than 10,000 nucleotides or a
15 complement thereof comprising a nucleotide sequence encoding β 3Gal-T5 (SEQ ID NO:9), or a function-conservative variant thereof.
6. An isolated nucleic acid of less than 10,000 nucleotides or a
complement thereof comprising nucleotides 73-930 as set forth in Figure 1, or a sequence-
20 conservative or a function-conservative variant thereof.
7. An isolated nucleic acid of less than 10,000 nucleotides or a
complement thereof consisting of at least 20 contiguous nucleotides selected from
nucleotides 1-115 and 428-1011 of SEQ ID NO:8.
- 25 8. An isolated nucleic acid of less than 10,000 nucleotides or a
complement thereof which hybridizes under preferred hybridization conditions with a
nucleic acid consisting of at least 20 contiguous nucleotides selected from nucleotides 1-115
and 428-1011 of SEQ ID NO:8.
- 30 9. A nucleic acid vector of less than 50,000 nucleotides comprising a
first nucleotide sequence identical to or derived from a second nucleotide sequence

encoding β 3Gal-T5 (SEQ ID NO:9) or a fragment thereof having at least 15 amino acid residues.

5 10. A nucleic acid vector of less than 10,000 nucleotides comprising a first nucleotide sequence identical to or derived from a second nucleotide sequence encoding β 3Gal-T5 (SEQ ID NO:9) or a fragment thereof having at least 120 amino acid residues.

10 11. The vector of Claim 10, wherein the first nucleotide sequence is operably linked to a transcriptional regulatory element.

 12. A nucleic acid vector of less than 50,000 nucleotides comprising the nucleotide sequence of Claim 5.

15 13. A nucleic acid vector of less than 50,000 nucleotides comprising the nucleotide sequence of Claim 6.

 14. A host cell comprising the nucleic acid vector of Claim 10.

20 15. A host cell stably transfected with the nucleic acid vector of Claim 11.

 16. The host cell of Claim 14, wherein the nucleic acid vector is stably
25 transfected.

 17. The host cell of Claim 14 which produces β 3Gal-T5 enzymatic activity.

30 18. The host cell of Claim 14 which is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell, an avian cell and a mammalian cell.

19. The host cell of Claim 17 which is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell, an avian cell and a mammalian cell.
- 5 20. The insect cell of Claim 19 which is a *Spodoptera frugiperda* cell.
21. The mammalian Cell of claim 19 which is a chinese hamster ovary cell.
- 10 22. A host cell comprising the nucleic acid vector of Claim 12.
23. A host cell comprising the nucleic acid vector of Claim 13.
24. A method for producing a β 3Gal-T5 polypeptide (SEQ ID NO:9), a
15 fragment thereof having at least 30 amino acid residues, or a function-conservative variant of the polypeptide or fragment, which comprises:
- (i) introducing into a host cell a nucleic acid encoding the β 3Gal-T5 polypeptide, fragment or variant;
- (ii) growing the host cell under conditions suitable for expression of the
20 nucleic acid introduced; and
- (iii) isolating the β 3Gal-T5 polypeptide, fragment or variant expressed by the host cell.
25. An isolated β 3Gal-T5 polypeptide (SEQ ID NO:9).
- 25 26. An isolated β 3Gal-T5 polypeptide (SEQ ID NO:9) or a fragment thereof having at least 5 amino acid residues.
27. An isolated β 3Gal-T5 polypeptide (SEQ ID NO:9), a fragment
30 thereof having at least 50 amino acid residues, or a function-conservative variant of the polypeptide or fragment.

28. An isolated β 3Gal-T5 polypeptide comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:9.
- 5 29. An isolated derivative or fragment of the polypeptide of Claim 28 consisting of at least 10 contiguous amino acids of the β 3Gal-T5 polypeptide.
30. The derivative or fragment of Claim 29 which displays one or more functional activities of the β 3Gal-T5 polypeptide.
- 10 31. The derivative or fragment of Claim 29 which is capable of immunospecific binding to an antibody raised against a β 3Gal-T5 polypeptide.
- 15 32. A fusion protein comprising a fragment of the β 3Gal-T5 polypeptide of Claim 28 consisting of at least 10 contiguous amino acids of the β 3Gal-T5 polypeptide fused by a covalent bond to an amino acid sequence of a second protein, which second protein is not a β 3Gal-T5 polypeptide.
- 20 33. An isolated galactosyltransferase capable of transferring galactose β 1-3 to an acceptor substrate selected from the group consisting of GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-Cer, Glc β 1-Cer, GalNAc β 1-4Gal β 1-4Glc β 1-Cer, GlcNAc β 1-3Gal β 1-4Glc β 1-Cer, and GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1-Cer.
- 25 34. An isolated β 3Gal-T5 polypeptide (SEQ ID NO:9), a fragment thereof or a function-conservative variant of the polypeptide or fragment which is capable of transferring galactose β 1-3 to GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-Cer.
- 30 35. A purified antibody or an antigen-binding fragment or derivative thereof capable of immunospecific binding to the polypeptide of any one of Claims 25-28 and not to another galactosyltransferase.

36. The antibody of Claim 35 which is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody and a humanized antibody.

5

37. The monoclonal antibody of Claim 36 which is UH9.

10

15

20

25

30

1/5

β3Gal-T5

```

-78 CCACCTCAGCCTCCTAGCATAAACTAGACACATCCTCATGCTTTTGAGGTCTAATCATTGGATTTTGTTCCTTTTCAG -1
1   M A F P K M R L M Y I C L L V L G A L C L Y Y S M N 26
1   ATGGCTTTCCCGAAGATGAGATTGATGTATATCTGCCTTCTGGTTCTGGGGGCTCTTTGTTTGTATTATAGCATGAAC 78
27   S L N P F K E Q S F V Y K K D G N F L K L P D T D C 52
79   AGTCTAAATCCTTTCAAAGAACAGTCCTTTGTTTACAAGAAAGACGGGAACCTTCCTTAAGCTCCCAGATACAGACTGC 156
53   R Q T P P F L V L L V T S S H K Q L A E R M A I R Q 78
157  AGGCAGACACCTCCCTTCCTCGTCCTGCTGGTGACCTCATCCCACAAACAGTTGGCTGAGCGCATGGCCATCCGGCAG 234
79   T W G K E R T V K G K Q L K T F F L L G T T S S A A 104
235  ACGTGGGGGAAAGAGAGGACGGTGAAGGGAAAGCAGCTGAAGACATTCTTCCTCCTGGGGACCACCAGCAGTGCAGCG 312
105  E T K E V D Q E S Q R H G D I I Q K D F L D V Y Y N* 130
313  GAAACAAAAGAGGTGGACCAGGAGAGCCAGCAGACACGGGGACATTATCCAGAAAGGATTTCCTAGACGTCTATTACAAT 390
131  L T L K T M M G I E W V H R F C P Q A A F V M K T D 156
391  CTGACCCTGAAGACCATGATGGGCATAGAAATGGGTCCATCGCTTTTGTCTCAGGGCGGCGTTTGTGATGAAAACAGAC 468
157  S D M F I N V D Y L T E L L L K K N* P T T R F F T G 182
469  TCAGACATGTTCAATGTTGACTATCTGACTGAAGTCTTCTGAAGAAAAACAGAACAACCAGGTTTTTCACTGGC 546
183  F L K L N E F P I R Q P F S K W F V S K S E Y P W D 208
547  TTCTTGAAACTCAATGAGTTTCCCATCAGGCAGCCATTAGCAAGTGTTTGTGAGTAAATCTGAATATCCGTGGGAC 624
209  R Y P P F C S G T G Y V F S G D V A S Q V Y N* V S K 234
625  AGGTACCCACCATTCTGCTCCGGCACCGGCTACGTGTTTTCTGGCGACGTGGCGAGTCAGGTGTACAATGTCTCCAAG 702
235  S V P Y I K L E D V F V G L C L E R L N I R L E E L 260
703  AGCGTCCCATACATTAAACTGGAAGACGTGTTTGTGGGGCTCTGCCTCGAAAGGCTGAACATCAGATTGGAGGAGCTC 780
261  H S Q P T F F P G G L R F S V C L F R R I V A C H F 286
781  CACTCCCAGCGACCTTTTTTCCAGGGGGCTTACGCTTCTCCGTATGCCTCTTCAGGAGGATCGTGGCCTGCCACTTC 858
287  I K P R T L L D Y W Q A L E N S R G E D C P P V * 310
859  ATCAAGCCTCGGACTCTCTTGGAATACTGGCAGGCTCTAGAGAATTCGCGGGGGGAGATTGTCCGCTGTCTGA... 933

```

FIGURE 1

```

βGal-T1 : -----HASKVSLVYVTVVCHASALVLSIT--RP : 28
βGal-T2 : NLOWRRHCCFAKHTWNAKRSFRTHLICVLSVLEFAMLEFNNHMDLPGRAGKKNPVYTTGCFRTKSENHSSLRNITKETVYQTLRP : 93
βGal-T3 : -----MAFKMAHYICULVLGALCLYFSMYS : 27
βGal-T4 : -----MOLNLFM--RLALAAHLLVIVITLPCW : 39
βGal-T5 : -----HASALMTVLPSRMSLSLSLSSLSFFVWYLSLP : 25

βGal-T1 : TSSYTGSG---KP---FSLTVAARKHFTFGNIR--TRPIHDSSEFLINERNKCEK--NIPETVLIISTTHKEFPDARQIRERUGDENNFNFI : 110
βGal-T2 : OTATNSNNTDLSPOCVTGLENTLSANGSIYKNG--TCHPNVYVVKVLIIMEREKCE--KSPFLLIAAEHGOIENRMAIRCTWGNESLAPCI : 103
βGal-T3 : -----LNR-----FKESFVYK-----DCNFKALPD--TDCMO--TPPEFVLVVTSSHKOLAEPMARISCTWGNERTVVKK : 09
βGal-T4 : -----HYNVIERVWHYFTEY---EPIYRODEHFTLRENSNSH--ONPEFVIVVTSNHSOVKARQIRERUGCEKKSWMGY : 110
βGal-T5 : -----LCEELSLSLASLLPAPASCPPLAPRLIPNO--EASGCPGAPPELITVCTAGYENLNQVNAIRASWGGUREANGI : 103

βGal-T1 : KIALFLHGGKNAOP-----VLNOMVECESQIFHDDIVEDEISVLLTLLTLLMGHRRVATFGSKAKYVKTTSSEIFVHMOMIYVYK : 193
βGal-T2 : QITHIFLGLSIKLN--G-YHQRALLESROYHDDHOOEVLDTYVLLTLLTLLMGHRRVATFGSKAKYVKTTSSEIFVHMOMIYVYK : 260
βGal-T3 : OLKTFELGTTSSA-----AETKEVDDESORHGDQKDELCVNVNLTLLTLLMGHRRVATFGSKAKYVKTTSSEIFVHMOMIYVYK : 172
βGal-T4 : EVLTFELGGOEAEK--DKMHALSLEDHLLYGDHROD--LDTNNLGLATILAFRWUTEFCNNAKVKKTTSSEIFVHMOMIYVYK : 196
βGal-T5 : RVQTLFELGEPNAQHPVWGSQGSOLAS--EAAAGGDLQANALCCSHNLETTATLSCGLNNAEKHCEHMRERVLKTSDDVYVNVPELVSEIVLRGRW : 196

βGal-T1 : -----PSTKPRR-----RYEGYVING--GPIEDVNSVYVMPNDIYF--DSHWPPFCSGTGVITSADVAELFKYKTLNTRDHL : 263
βGal-T2 : -----POLPRRH-----NYEGYVING--GPIEDVNSVYVMPNDIYF--DSHWPPFCSGTGVITSADVAELFKYKTLNTRDHL : 339
βGal-T3 : -----KNITTH-----FEGFLKNEFEIROPFSHPVSKSEYF--WDRVPPFCSGTGVITSADVAELFKYKTLNTRDHL : 241
βGal-T4 : -----LNHSEK-----FEGFLKNEFEIROPFSHPVSKSEYF--FVTPPPFCSGTGVITSADVAELFKYKTLNTRDHL : 265
βGal-T5 : GQVNSTEFOREAEQREGGVVNSERVPLLVILGRVHNRVWSESRTTGGRRHVSSEQWPTWTGTPPPYASGTCGVLSASAVQILKVASRAPLHPI : 289

βGal-T1 : EDVYVGLCLRMCTGTHFQ--N-SGNNMKHAYSLGRYRRLVTVHOISPEEMHRIHMDSSKKHLG : 326
βGal-T2 : EDVYVGLCLRMCTGTHFQ--N-SGNNMKHAYSLGRYRRLVTVHOISPEEMHRIHMDSSKKHLG : 422
βGal-T3 : EDVYVGLCLRMCTGTHFQ--N-SGNNMKHAYSLGRYRRLVTVHOISPEEMHRIHMDSSKKHLG : 310
βGal-T4 : EDVYVGLCLRMCTGTHFQ--N-SGNNMKHAYSLGRYRRLVTVHOISPEEMHRIHMDSSKKHLG : 331
βGal-T5 : EDVYVGLCLRMCTGTHFQ--N-SGNNMKHAYSLGRYRRLVTVHOISPEEMHRIHMDSSKKHLG : 370

```

FIGURE 2




FIGURE 3




FIGURE 4

5/5




FIGURE 5

SEQUENCE LISTING

<110> Clausen, Henrik
Amado, Margarita

<120> UDP-GALACTOSE: BETA-N-ACETYL-GLUCOSAMINE BETA 1,3
GALACTOSYLTRANSFERASES, BETAGAL-T5

<130> 7188-157

<140>
<141>

<160> 17

<170> PatentIn Ver. 2.0

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 1
cttccttaag ctcccagata c 21

<210> 2
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 2
gtttccgctg cactgcactg ctggtg 26

<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 3
atgtacagtc taaatccttt c 21

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 4

tcagacaggc ggacaatctt c

21

<210> 5

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 5

atggctcccg aagatgag

18

<210> 6

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 6

cagcgagggt ctagagtttc c

21

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 7

gaaatccacg ccagaatgtc g

21

<210> 8

<211> 1011

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (79) .. (1008)

<400> 8

ccacctcagc ctcttagcat aaaactagac acatcctcat gcttttgagg tctaattcatt 60

ggattttgtt cctttcag atg gct ttc ccg aag atg aga ttg atg tat atc 111

Met Ala Phe Pro Lys Met Arg Leu Met Tyr Ile

1

5

10

tgc ctt ctg gtt ctg ggg gct ctt tgt ttg tat ttt agc atg tac agt Cys Leu Leu Val Leu Gly Ala Leu Cys Leu Tyr Phe Ser Met Tyr Ser	159
15 20 25	
cta aat cct ttc aaa gaa cag tcc ttt gtt tac aag aaa gac ggg aac Leu Asn Pro Phe Lys Glu Gln Ser Phe Val Tyr Lys Lys Asp Gly Asn	207
30 35 40	
ttc ctt aag ctc cca gat aca gac tgc agg cag aca cct ccc ttc ctc Phe Leu Lys Leu Pro Asp Thr Asp Cys Arg Gln Thr Pro Pro Phe Leu	255
45 50 55	
gtc ctg ctg gtg acc tca tcc cac aaa cag ttg gct gag cgc atg gcc Val Leu Leu Val Thr Ser His Lys Gln Leu Ala Glu Arg Met Ala	303
60 65 70 75	
atc cgg cag acg tgg ggg aaa gag agg acg gtg aag gga aag cag ctg Ile Arg Gln Thr Trp Gly Lys Glu Arg Thr Val Lys Gly Lys Gln Leu	351
80 85 90	
aag aca ttc ttc ctc ctg ggg acc acc agc agt gca gcg gaa aca aaa Lys Thr Phe Phe Leu Leu Gly Thr Thr Ser Ser Ala Ala Glu Thr Lys	399
95 100 105	
gag gtg gac cag gag agc cag cga cac ggg gac att atc cag aag gat Glu Val Asp Gln Glu Ser Gln Arg His Gly Asp Ile Ile Gln Lys Asp	447
110 115 120	
ttc cta gac gtc tat tac aat ctg acc ctg aag acc atg atg ggc ata Phe Leu Asp Val Tyr Tyr Asn Leu Thr Leu Lys Thr Met Met Gly Ile	495
125 130 135	
gaa tgg gtc cat cgc ttt tgt cct cag gcg gcg ttt gtg atg aaa aca Glu Trp Val His Arg Phe Cys Pro Gln Ala Ala Phe Val Met Lys Thr	543
140 145 150 155	
gac tca gac atg ttc atc aat gtt gac tat ctg act gaa ctg ctt ctg Asp Ser Asp Met Phe Ile Asn Val Asp Tyr Leu Thr Glu Leu Leu Leu	591
160 165 170	
aag aaa aac aga aca acc agg ttt ttc act ggc ttc ttg aaa ctc aat Lys Lys Asn Arg Thr Thr Arg Phe Phe Thr Gly Phe Leu Lys Leu Asn	639
175 180 185	
gag ttt ccc atc agg cag cca ttc agc aag tgg ttt gtc agt aaa tct Glu Phe Pro Ile Arg Gln Pro Phe Ser Lys Trp Phe Val Ser Lys Ser	687
190 195 200	
gaa tat ccg tgg gac agg tac cca cca ttc tgc tcc ggc acc ggc tac Glu Tyr Pro Trp Asp Arg Tyr Pro Pro Phe Cys Ser Gly Thr Gly Tyr	735
205 210 215	
gtg ttt tct ggc gac gtg gcg agt cag gtg tac aat gtc tcc aag agc Val Phe Ser Gly Asp Val Ala Ser Gln Val Tyr Asn Val Ser Lys Ser	783
220 225 230 235	

<400> 9															
Met	Ala	Phe	Pro	Lys	Met	Arg	Leu	Met	Tyr	Ile	Cys	Leu	Leu	Val	Leu
1				5					10					15	
Gly	Ala	Leu	Cys	Leu	Tyr	Phe	Ser	Met	Tyr	Ser	Leu	Asn	Pro	Phe	Lys
			20					25					30		
Glu	Gln	Ser	Phe	Val	Tyr	Lys	Lys	Asp	Gly	Asn	Phe	Leu	Lys	Leu	Pro
		35					40					45			
Asp	Thr	Asp	Cys	Arg	Gln	Thr	Pro	Pro	Phe	Leu	Val	Leu	Leu	Val	Thr
	50					55					60				
Ser	Ser	His	Lys	Gln	Leu	Ala	Glu	Arg	Met	Ala	Ile	Arg	Gln	Thr	Trp
65					70					75					80
Gly	Lys	Glu	Arg	Thr	Val	Lys	Gly	Lys	Gln	Leu	Lys	Thr	Phe	Phe	Leu
				85					90					95	
Leu	Gly	Thr	Thr	Ser	Ser	Ala	Ala	Glu	Thr	Lys	Glu	Val	Asp	Gln	Glu
			100					105					110		
Ser	Gln	Arg	His	Gly	Asp	Ile	Ile	Gln	Lys	Asp	Phe	Leu	Asp	Val	Tyr
		115					120					125			
Tyr	Asn	Leu	Thr	Leu	Lys	Thr	Met	Met	Gly	Ile	Glu	Trp	Val	His	Arg
	130					135					140				
Phe	Cys	Pro	Gln	Ala	Ala	Phe	Val	Met	Lys	Thr	Asp	Ser	Asp	Met	Phe
145					150					155					160

Ile Asn Val Asp Tyr Leu Thr Glu Leu Leu Leu Lys Lys Asn Arg Thr
 165 170 175
 Thr Arg Phe Phe Thr Gly Phe Leu Lys Leu Asn Glu Phe Pro Ile Arg
 180 185 190
 Gln Pro Phe Ser Lys Trp Phe Val Ser Lys Ser Glu Tyr Pro Trp Asp
 195 200 205
 Arg Tyr Pro Pro Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser Gly Asp
 210 215 220
 Val Ala Ser Gln Val Tyr Asn Val Ser Lys Ser Val Pro Tyr Ile Lys
 225 230 235 240
 Leu Glu Asp Val Phe Val Gly Leu Cys Leu Glu Arg Leu Asn Ile Arg
 245 250 255
 Leu Glu Glu Leu His Ser Gln Pro Thr Phe Phe Pro Gly Gly Leu Arg
 260 265 270
 Phe Ser Val Cys Leu Phe Arg Arg Ile Val Ala Cys His Phe Ile Lys
 275 280 285
 Pro Arg Thr Leu Leu Asp Tyr Trp Gln Ala Leu Glu Asn Ser Arg Gly
 290 295 300
 Glu Asp Cys Pro Pro Val
 305 310

<210> 10
 <211> 422
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Leu Gln Trp Arg Arg Arg His Cys Cys Phe Ala Lys Met Thr Trp
 1 5 10 15
 Asn Ala Lys Arg Ser Leu Phe Arg Thr His Leu Ile Gly Val Leu Ser
 20 25 30
 Leu Val Phe Leu Phe Ala Met Phe Leu Phe Phe Asn His His Asp Trp
 35 40 45
 Leu Pro Gly Arg Ala Gly Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe
 50 55 60
 Arg Gly Phe Arg Ser Thr Lys Ser Glu Thr Asn His Ser Ser Leu Arg
 65 70 75 80
 Asn Ile Trp Lys Glu Thr Val Pro Gln Thr Leu Arg Pro Gln Thr Ala
 85 90 95
 Thr Asn Ser Asn Asn Thr Asp Leu Ser Pro Gln Gly Val Thr Gly Leu
 100 105 110

Glu Asn Thr Leu Ser Ala Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr
 115 120 125
 Gly His Pro Asn Ser Tyr His Phe Lys Tyr Ile Ile Asn Glu Pro Glu
 130 135 140
 Lys Cys Gln Glu Lys Ser Pro Phe Leu Ile Leu Leu Ile Ala Ala Glu
 145 150 155 160
 Pro Gly Gln Ile Glu Ala Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn
 165 170 175
 Glu Ser Leu Ala Pro Gly Ile Gln Ile Thr Arg Ile Phe Leu Leu Gly
 180 185 190
 Leu Ser Ile Lys Leu Asn Gly Tyr Leu Gln Arg Ala Ile Leu Glu Glu
 195 200 205
 Ser Arg Gln Tyr His Asp Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr
 210 215 220
 Tyr Asn Leu Thr Ile Lys Thr Leu Met Gly Met Asn Trp Val Ala Thr
 225 230 235 240
 Tyr Cys Pro His Ile Pro Tyr Val Met Lys Thr Asp Ser Asp Met Phe
 245 250 255
 Val Asn Thr Glu Tyr Leu Ile Asn Lys Leu Leu Lys Pro Asp Leu Pro
 260 265 270
 Pro Arg His Asn Tyr Phe Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro
 275 280 285
 Asn Arg Asn Lys Asp Ser Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro
 290 295 300
 Ser Glu Arg Tyr Pro Val Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser
 305 310 315 320
 Gly Asp Leu Ala Glu Lys Ile Phe Lys Val Ser Leu Gly Ile Arg Arg
 325 330 335
 Leu His Leu Glu Asp Val Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg
 340 345 350
 Ile Asp Pro Val Pro Pro Pro Asn Glu Phe Val Phe Asn His Trp Arg
 355 360 365
 Val Ser Tyr Ser Ser Cys Lys Tyr Ser His Leu Ile Thr Ser His Gln
 370 375 380
 Phe Gln Pro Ser Glu Leu Ile Lys Tyr Trp Asn His Leu Gln Gln Asn
 385 390 395 400
 Lys His Asn Ala Cys Ala Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr
 405 410 415

Arg His Arg Lys Leu His
420

<210> 11
<211> 326
<212> PRT
<213> Homo sapiens

<400> 11
Met Ala Ser Lys Val Ser Cys Leu Tyr Val Leu Thr Val Val Cys Trp
1 5 10 15

Ala Ser Ala Leu Trp Tyr Leu Ser Ile Thr Arg Pro Thr Ser Ser Tyr
20 25 30

Thr Gly Ser Lys Pro Phe Ser His Leu Thr Val Ala Arg Lys Asn Phe
35 40 45

Thr Phe Gly Asn Ile Arg Thr Arg Pro Ile Asn Pro His Ser Phe Glu
50 55 60

Phe Leu Ile Asn Glu Pro Asn Lys Cys Glu Lys Asn Ile Pro Phe Leu
65 70 75 80

Val Ile Leu Ile Ser Thr Thr His Lys Glu Phe Asp Ala Arg Gln Ala
85 90 95

Ile Arg Glu Thr Trp Gly Asp Glu Asn Asn Phe Lys Gly Ile Lys Ile
100 105 110

Ala Thr Leu Phe Leu Leu Gly Lys Asn Ala Asp Pro Val Leu Asn Gln
115 120 125

Met Val Glu Gln Glu Ser Gln Ile Phe His Asp Ile Ile Val Glu Asp
130 135 140

Phe Ile Asp Ser Tyr His Asn Leu Thr Leu Lys Thr Leu Met Gly Met
145 150 155 160

Arg Trp Val Ala Thr Phe Cys Ser Lys Ala Lys Tyr Val Met Lys Thr
165 170 175

Asp Ser Asp Ile Phe Val Asn Met Asp Asn Leu Ile Tyr Lys Leu Leu
180 185 190

Lys Pro Ser Thr Lys Pro Arg Arg Arg Tyr Phe Thr Gly Tyr Val Ile
195 200 205

Asn Gly Gly Pro Ile Arg Asp Val Arg Ser Lys Trp Tyr Met Pro Arg
210 215 220

Asp Leu Tyr Pro Asp Ser Asn Tyr Pro Pro Phe Cys Ser Gly Thr Gly
225 230 235 240

Tyr Ile Phe Ser Ala Asp Val Ala Glu Leu Ile Tyr Lys Thr Ser Leu
245 250 255

His Thr Arg Leu Leu His Leu Glu Asp Val Tyr Val Gly Leu Cys Leu
 260 265 270
 Arg Lys Leu Gly Ile His Pro Phe Gln Asn Ser Gly Phe Asn His Trp
 275 280 285
 Lys Met Ala Tyr Ser Leu Cys Arg Tyr Arg Arg Val Ile Thr Val His
 290 295 300
 Gln Ile Ser Pro Glu Glu Met His Arg Ile Trp Asn Asp Met Ser Ser
 305 310 315 320
 Lys Lys His Leu Arg Cys
 325

<210> 12
 <211> 331
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Ala Ser Ala Leu Trp Thr Val Leu Pro Ser Arg Met Ser Leu Arg
 1 5 10 15
 Ser Leu Lys Trp Ser Leu Leu Leu Leu Ser Leu Leu Ser Phe Phe Val
 20 25 30
 Met Trp Tyr Leu Ser Leu Pro His Tyr Asn Val Ile Glu Arg Val Asn
 35 40 45
 Trp Met Tyr Phe Tyr Glu Tyr Glu Pro Ile Tyr Arg Gln Asp Phe His
 50 55 60
 Phe Thr Leu Arg Glu His Ser Asn Cys Ser His Gln Asn Pro Phe Leu
 65 70 75 80
 Val Ile Leu Val Thr Ser His Pro Ser Asp Val Lys Ala Arg Gln Ala
 85 90 95
 Ile Arg Val Thr Trp Gly Glu Lys Lys Ser Trp Trp Gly Tyr Glu Val
 100 105 110
 Leu Thr Phe Phe Leu Leu Gly Gln Glu Ala Glu Lys Glu Asp Lys Met
 115 120 125
 Leu Ala Leu Ser Leu Glu Asp Glu His Leu Leu Tyr Gly Asp Ile Ile
 130 135 140
 Arg Gln Asp Phe Leu Asp Thr Tyr Asn Asn Leu Thr Leu Lys Thr Ile
 145 150 155 160
 Met Ala Phe Arg Trp Val Thr Glu Phe Cys Pro Asn Ala Lys Tyr Val
 165 170 175
 Met Lys Thr Asp Thr Asp Val Phe Ile Asn Thr Gly Asn Leu Val Lys
 180 185 190

Tyr Leu Leu Asn Leu Asn His Ser Glu Lys Phe Phe Thr Gly Tyr Pro
 195 200 205
 Leu Ile Asp Asn Tyr Ser Tyr Arg Gly Phe Tyr Gln Lys Thr His Ile
 210 215 220
 Ser Tyr Gln Glu Tyr Pro Phe Lys Val Phe Pro Pro Tyr Cys Ser Gly
 225 230 235 240
 Leu Gly Tyr Ile Met Ser Arg Asp Leu Val Pro Arg Ile Tyr Glu Met
 245 250 255
 Met Gly His Val Lys Pro Ile Lys Phe Glu Asp Val Tyr Val Gly Ile
 260 265 270
 Cys Leu Asn Leu Leu Lys Val Asn Ile His Ile Pro Glu Asp Thr Asn
 275 280 285
 Leu Phe Phe Leu Tyr Arg Ile His Leu Asp Val Cys Gln Leu Arg Arg
 290 295 300
 Val Ile Ala Ala His Gly Phe Ser Ser Lys Glu Ile Ile Thr Phe Trp
 305 310 315 320
 Gln Val Met Leu Arg Asn Thr Thr Cys His Tyr
 325 330

<210> 13
 <211> 378
 <212> PRT
 <213> Homo sapiens

<400> 13
 Met Gln Leu Arg Leu Phe Arg Arg Leu Leu Leu Ala Ala Leu Leu Leu
 1 5 10 15
 Val Ile Val Trp Thr Leu Phe Gly Pro Ser Gly Leu Gly Glu Glu Leu
 20 25 30
 Leu Ser Leu Ser Leu Ala Ser Leu Leu Pro Ala Pro Ala Ser Pro Gly
 35 40 45
 Pro Pro Leu Ala Leu Pro Arg Leu Leu Ile Pro Asn Gln Glu Ala Cys
 50 55 60
 Ser Gly Pro Gly Ala Pro Pro Phe Leu Leu Ile Leu Val Cys Thr Ala
 65 70 75 80
 Pro Glu Asn Leu Asn Gln Arg Asn Ala Ile Arg Ala Ser Trp Gly Gly
 85 90 95
 Leu Arg Glu Ala Arg Gly Leu Arg Val Gln Thr Leu Phe Leu Leu Gly
 100 105 110
 Glu Pro Asn Ala Gln His Pro Val Trp Gly Ser Gln Gly Ser Asp Leu
 115 120 125

Ala Ser Glu Ser Ala Ala Gln Gly Asp Ile Leu Gln Ala Ala Phe Gln
 130 135 140
 Asp Ser Tyr Arg Asn Leu Thr Leu Lys Thr Leu Ser Gly Leu Asn Trp
 145 150 155 160
 Ala Glu Lys His Cys Pro Met Ala Arg Tyr Val Leu Lys Thr Asp Asp
 165 170 175
 Asp Val Tyr Val Asn Val Pro Glu Leu Val Ser Glu Leu Val Leu Arg
 180 185 190
 Gly Gly Arg Trp Gly Gln Trp Glu Arg Ser Thr Glu Pro Gln Arg Glu
 195 200 205
 Ala Glu Gln Glu Gly Gly Gln Val Leu His Ser Glu Glu Val Pro Leu
 210 215 220
 Leu Tyr Leu Gly Arg Val His Trp Arg Val Asn Pro Ser Arg Thr Pro
 225 230 235 240
 Gly Gly Arg Gly Arg Val Ser Glu Glu Gln Trp Pro His Thr Trp Gly
 245 250 255
 Pro Phe Pro Pro Tyr Ala Ser Gly Thr Gly Tyr Val Leu Ser Ala Ser
 260 265 270
 Ala Val Gln Leu Ile Leu Lys Val Ala Ser Arg Ala Pro Leu Leu Pro
 275 280 285
 Leu Glu Asp Val Phe Val Gly Val Ser Ala Arg Arg Gly Gly Leu Ala
 290 295 300
 Pro Thr Gln Cys Val Lys Leu Ala Gly Ala Thr His Tyr Pro Leu Asp
 305 310 315 320
 Arg Cys Cys Tyr Gly Lys Phe Leu Leu Thr Ser His Arg Leu Asp Pro
 325 330 335
 Trp Lys Met Gln Glu Ala Trp Lys Leu Val Gly Gly Ser Asp Gly Glu
 340 345 350
 Arg Thr Ala Pro Phe Cys Ser Trp Phe Gln Gly Val Leu Gly Ile Leu
 355 360 365
 Arg Cys Arg Ala Ile Ala Trp Leu Gln Ser
 370 375

<210> 14

<211> 30

<212> DNA

<213> Homo sapiens

<400> 14

cggggtaccg gaaacgatga aatatacaag

30

<210> 15
<211> 40
<212> DNA
<213> Homo sapiens

<400> 15
ggcggatcca ggcagatcac agccaagaga acccaaaacg

40

<210> 16
<211> 40
<212> DNA
<213> Homo sapiens

<400> 16
gcggatccca ggcagatcac agccaagaga acccaaaacg

40

<210> 17
<211> 41
<212> DNA
<213> Homo sapiens

<400> 17
gcggatcccc aggcagatca cagccaagag aacccaaaac g

41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26807

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/00, 9/10, 9/24, 9/38

US CL : 435/69.1, 183, 193, 200, 207

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 183, 193, 200, 207

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN FILE REGISTRY, BIOSIS, MEDLINE, EMBASE, CA, CAPLUS, TOXLINE, TOXLIT, USPATFULL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank on STN, Accession Number AJ003597, SZULZEWSKY et al., 'An integrated transcript map for the whole human chromosome 21', abstract, 04 December 1997, see entire abstract.	1-25
X	Database GenBank on STN, Accession Number AF064860, RUMP et al., 'Direct Submission', abstract, 02 June 1998, see entire abstract.	1-25
Y	AMADO et al. A family of human β 3-galactosyltransferases. Characterization of four members of a UDP-galactose:beta-N-acetylglucosamine/ β -N-acetyl-galactosamine β -1,3-galactosyltransferase family. J. Biol. Chem. 22 May 1998, Vol. 273, No. 21, pages 12770-12778, see entire document.	1-25

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 JANUARY 2000

Date of mailing of the international search report

11 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

MANJUNATH RAO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26807

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HENNET et al. Genomic cloning and expression of three murine UDP-glucose:β-N-acetylglucosamine β1,3-galactosyltransferase genes. J. Biol. Chem. 02 January 1998, Vol. 273, No. 1, pages 58-65, see entire document.	1-25

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26807

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/26807

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-24, drawn to polynucleotides, vectors and host cells.

Group II, claim 25, drawn to polypeptide.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is a product; this shares the special technical feature of the DNA molecules, which group II does not share.

Group II is a product; this shares the special technical feature of a protein, which group I does not share.